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Executive Summary
The potential impact of COVID-19 on the drug 
markets of East and Southeast Asia
At the time of writing this report, East and Southeast 
Asia is experiencing the full-blown effects of the 
COVID-19 pandemic. The pandemic’s profound 
implications, including a reduced volume of trade 
and travel, widespread economic recession, 
imposition of strict social distancing policies 
and a reordering of governments’ imperatives 
and resources, will more likely than not have a 
far-reaching impact on the drug markets in the 
region. There are three considerations which are 
highlighted for readers to keep in mind when 
assessing and responding to the impact of the 
pandemic on the ever-expanding regional drug 
market in the upcoming months and possibly years.
Recognizing the flexibility of illicit markets to quickly 
reconstitute themselves in times of crisis, we should 
first exercise caution in quickly attributing drug-
related trends as a direct or indirect consequence 
of the pandemic. A significant statistical change 
observed during this period may not necessarily 
equate to a real change in demand or supply, and 
may imply changes to drug trafficking-related 
methods or other factors. Efforts will be required 
at the national, regional and international levels 
to carefully and accurately interpret the situation 
and understand how the regional drug market 
evolves in the wake of the pandemic. Secondly, 
given that extreme levels of synthetic drug and 
methamphetamine manufacture take place within 
the region, in-part a result of economies of scale 
and limited government control in the Golden 
Triangle, supply will continue. In particular, illicit 
supply chains of precursor chemicals for the 
manufacture of illicit drugs in the Golden Triangle 
are not expected to be disrupted for the foreseeable 
future, as sourcing of chemicals largely involves 
direct diversion from industry and trafficking, 
not diversion from licit trade channels. However, 
stringent social distancing policies and economic 
hardship may have an adverse impact on localized 
(street level) supply and demand patterns. Thirdly, 
the re-ordering of governments’ imperatives and 
resources towards the pandemic may jeopardize 
recent efforts to strengthen drug prevention and 
treatment programmes. A reduction in resources 
to these programmes may render those at the 
margins of society even more vulnerable and 
undermine drug demand reduction efforts.
Major developments in the regional synthetic 
drug market 
Methamphetamine 
Recent developments clearly demonstrate that 
the ongoing expansion of the methamphetamine 
market in East and Southeast Asia has been driven 
by supply. The growing signs of an intensification 
of methamphetamine manufacturing activity 
within and around the Golden Triangle, as well 
as nearby countries like Cambodia and Viet Nam, 
and a corresponding decrease in the number of 
production facilities dismantled in other parts 
of the region, indicates that methamphetamine 
manufacture is now consolidated into the lower 
Mekong region. This trend should be of concern to 
the international community given vital institutional 
integrity, capacity and resource deficits which make 
several countries in the region attractive targets for 
organized crime groups. 
Countries in East and Southeast Asia have 
collectively witnessed sustained increases in 
seizures of methamphetamine over the last decade, 
more than any other part of the world. At the time 
of writing, countries in the region have already 
confirmed seizures of 115 tons of the drug in 2019. 
It is important to note that the figure does not 
include any data from China, which seized nearly 
30 tons on average over the last five years. 
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Figure 1. Seizures of methamphetamine in East and 
Southeast Asia, 2011-2019*
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Note: Data for 2019 include only those confirmed by countries 
in the region. For more information, see footnote 13 of the 
regional chapter. 
Source: UNODC, responses to the annual report questionnaire; 
Official communication with the Supreme Prosecutors’ Office 
(SPO) of the Republic of Korea, February 2020; National Police 
Agency (NPA) of Japan, “Drug Control in Japan”, presented 
at the 25th Asia-Pacific Operational Drug Enforcement 
Conference, Tokyo, Japan, February 2020; Comparison of 2019 
and 2018 crime situation, Hong Kong Police Force, (accessed at 
https://www.police.gov.hk/info/doc/overcrim.pdf). 
One of the major developments observed in the 
methamphetamine market is the increase in 
supply of methamphetamine in crystalline form, 
particularly in Southeast Asia, which has been 
more pronounced and persistent compared to 
methamphetamine in tablet form. Preliminary data 
show that at least 63 tons of the drug were seized 
in Southeast Asia in 2019, more than a 50 per cent 
increase compared to the preceding year. 
Organized crime groups have adapted major 
methamphetamine trafficking routes in response 
to law enforcement operations. In 2019, increases 
in trafficking along the western border of Thailand 
were observed by the authorities, while at the same 
time, increased quantities of methamphetamine 
were trafficked through Lao PDR and Viet Nam, 
which reported record seizures. The increases 
demonstrate that both countries have become 
major gateways for trafficking of the drug within the 
region. Maritime drug trafficking remained active 
throughout 2019, in particular along the Andaman 
Sea and Malacca Strait, to reach crystalline 
methamphetamine markets in Indonesia and 
Malaysia as well as onward trafficking to Australia, 
Japan and New Zealand. 
Growing methamphetamine manufacture in 
East and Southeast Asia would not be possible 
without a matching surge in precursor chemical 
diversion and trafficking. However, recent seizure 
trends of methamphetamine precursor chemicals 
are not commensurate with the trends in 
methamphetamine seizures, signaling difficulties 
in coping with increasing diversion, trafficking and 
illicit manufacture of key precursor chemicals. 
A vast majority of recent seizures reported by 
Myanmar authorities point to areas bordering 
China as being heavily exploited by transnational 
organized crime groups for precursor trafficking. 
Another significant entry point for chemicals to 
Myanmar is the southern Shan State on the border 
with Thailand. 
The types of chemicals seized in Myanmar in recent 
years also point to new synthesis methods being 
used for the manufacture of methamphetamine. 
However, drug forensic profiles reported by 
countries in the region indicate that ephedrine 
and pseudoephedrine remain the major 
precursor chemicals used for the manufacture 
of methamphetamine in the region. This shows 
significant intelligence gaps in addressing diversion, 
trafficking and illicit manufacture of these key 
precursor chemicals.   
Beyond this, methamphetamine has become 
cheaper, reaching its lowest price points in the 
last decade in East and Southeast Asia. Decreases 
in prices of crystalline methamphetamine were 
also observed in Australia, New Zealand, and the 
Republic of Korea, all of which have been important 
destinations for the drug from the region. While 
prices of methamphetamine have decreased 
substantially, purities remain high and have even 
increased in a few countries. Simply put, organized 
crime groups have been able to provide better 
quality methamphetamine products at cheaper 
prices, indicating reduced production costs and a 
change in the business model. 
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Figure 2. Changes in typical prices of 
methamphetamine tablets of selected countries 
in Southeast Asia, 2011, 2015 and 2019 
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Note: The high-low bars represent the upper and lower limits 
of the price range for those countries which reported such 
range in addition to the typical price; data in the table are 
not adjusted with purities. For the purpose of this figure, a 
mid-point of upper and lower limit was used when data were 
reported in a range format.
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; Official communication with NACD of Cambodia, 
LCDC of Lao PDR, CCDAC of Myanmar, and ONCB of Thailand, 
February 2020. 
The decreasing price of methamphetamine 
occurring during a time of economic growth and 
rising income levels has potentially increased 
affordability of the drug in East and Southeast Asia. 
A practical consequence now affecting individual 
users is that some can afford to purchase larger 
quantities and or higher purity versions of the drug. 
If caught, those with larger quantities may pass 
national legal thresholds that differentiate between 
amounts intended for personal consumption and 
those indicating intent to supply (trafficking) – 
potentially leading to a larger number of drug users 
charged with trafficking offences.
Ecstasy 
MDMA manufacture does not appear to be 
significant in East and Southeast Asia, however, as 
with methamphetamine there are strong indications 
of increased production in the lower Mekong region, 
indicating a migration of MDMA manufacture from 
maritime Southeast Asian countries. In addition to 
“ecstasy” being manufactured within the region, 
trafficking of the drug originating in other regions, 
in particular from Europe, continues to be reported 
in East and Southeast Asia. 
Increases in seizures of “ecstasy” were observed 
in several countries in East and Southeast Asia, 
including Cambodia, Japan, Malaysia, the Republic 
of Korea, and Thailand. Based on preliminary data 
for 2019, at least 4.7 million “ecstasy” tablets were 
seized in the region, with about 90 per cent of the 
total seized by Cambodia, Indonesia, Hong Kong, 
China, and Malaysia. 
While the use of “ecstasy” is not yet widespread 
in East and Southeast Asia, there are indications 
of increased use of the drug. Expert perceptions 
of “ecstasy” use reported from countries including 
Brunei Darussalam, Cambodia, Hong Kong, 
China, Japan, Singapore, and Viet Nam, indicate 
its increased use in recent years. One notable 
development in the region’s “ecstasy” market is 
the high proportion of female users as opposed to 
other major illicit drugs consumed in the region, 
such as methamphetamine and heroin.
“Ecstasy” has also reportedly become purer, and 
crystalline MDMA, associated with an increased 
risk of overdose events in other regions, appears to 
be available in East and Southeast Asia. In addition, 
drug products in liquid form containing MDMA in 
combination with other synthetic drugs have been 
found in the region.
New Psychoactive Substances (NPS)
The number of NPS, including potent synthetic 
opioids, reported from the region has increased 
steadily. By the end of 2019, a total of 461 
different NPS were reported by countries in East 
and Southeast Asia. However, the number of NPS 
detected in some countries in the region, including 
Cambodia, Lao PDR, and Myanmar remain limited, 
in part attributable to their limited capacity to 
identify these substances.
The number of NPS with opioid effects identified 
in East and Southeast Asia has increased gradually 
in recent years. While there were only three 
synthetic opioids identified in the region by 2014, 
the number increased to 28 substances by 2019. 
Some synthetic opioids identified in the region 
are extremely potent and have been implicated in 
overdose deaths outside the region, particularly in 
North America and to a lesser extent in Europe. 
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Figure 3. Emergence of NPS with opioid effects in East 
and Southeast Asia, 2014-2019* 
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Source(s): UNODC EWA on NPS. 
There is little information relating to overdose 
deaths associated with the non-medical use 
of synthetic opioids in East and Southeast Asia 
despite their steady emergence in recent years. 
However, there are already some indications of 
the availability of potent NPS with opioid effect in 
the regional drug market, and recent retrospective 
forensic data of autopsy cases from Thailand 
have shown the concurrent use of fentanyl with 
benzodiazepines and methamphetamine. Although 
it is unclear what proportion was associated with 
the non-medical use of synthetic opioids, the 
findings should be cause for concern. 
While the non-medical use of ketamine has long 
been a challenge for East and Southeast Asia, 
there have been changes in the ketamine market 
in recent years. As with methamphetamine, 
seizures of ketamine have increased significantly 
in Southeast Asia since 2015. The steep surge in 
seizures of ketamine in Southeast Asia has been 
primarily driven by substantial quantities of the 
drug being illicitly manufactured in, and trafficked 
from, Myanmar. Although most of the ketamine 
available in the regional drug market is being 
supplied from within the region, there are also 
indications pointing to supply routes from other 
regions, including South Asia and Europe. 
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Synthetic Drugs in East and Southeast Asia
1Introduction
This report presents the most current information 
available on synthetic drug manufacture, trafficking 
and demand in East and Southeast Asia with data 
from 2019 and in some cases up to the first quarter 
of 2020, when COVID-19 became a pandemic. The 
region has experienced a massive expansion of illicit 
drug supply in recent years as illicit manufacturing 
has become more sophisticated and the scale of 
facilities has expanded, the purity of drugs has 
increased, and prices have dropped - a worrisome 
scenario in a region where drug treatment has not 
always been available or affordable for those who 
need it.
 
Against this backdrop, it needs to be considered 
how the implications of the COVID-19 pandemic, 
including reduced trade flows and different scrutiny 
of travellers, economic fallout due to lost income 
and lost jobs, and personal movement restrictions, 
impact illicit drug supply and demand in the region. 
What are the opportunities for organized crime 
offered by a refocussing of government attention to 
public health and screening at borders, the closure 
and slowdown of many government services, 
home-office arrangements for many parts of the 
workforce, and an increase in on-line activities and 
business? And what will the impact be on those 
who are already in drug treatment or urgently need 
it? 
First, not every fluctuation encountered in the 
coming months in terms of drug seizures, prices, 
drug-related arrests or deaths, will be a direct or 
indirect consequence of the COVID-19 pandemic. 
Organized crime groups active in the region have 
shown a high degree of flexibility to respond to 
shortages of supplies, raising risk levels on certain 
trafficking routes. The flexibility of the illicit 
economy, which does not have to wait for new 
rules and regulations to enter into force, should 
also not be underestimated. As the report finds, 
a large proportion of methamphetamine, still the 
main synthetic drug of concern in the region, is 
manufactured, trafficked and consumed in the 
region, without the need for globalized supply 
chains. Trafficking in the lower Mekong region 
also takes place in a variety of ways across borders 
which are porous and difficult to control, and 
cross-border movements in many places will not 
be significantly hindered by COVID-19 measures. 
While containerized trafficking exists, it is just 
one of many methods used, and the impact of 
reduced container trade may be limited. Where 
movements are significantly affected, e.g. couriers 
and body packing through airports, routes and 
methods will change quickly, leading to an initial 
statistical reduction in seizures but without a real 
change in terms of supply. Additional efforts will be 
required at the national, regional and international 
level to carefully analyse methods and trends to 
understand changes to drug markets in the wake of 
the COVID-19 pandemic. 
Secondly, given that extreme levels of synthetic drug 
production take place within the region, in-part a 
result of limited government control in the Golden 
Triangle, trafficking will continue at high volumes. 
In particular, the supply of precursor chemicals is 
not likely to be disrupted for the foreseeable future 
because sourcing of chemicals by major organized 
crime groups is largely through direct diversion 
from industry within the region and subsequent 
trafficking, not diversion from licit overseas trade 
channels. At the same time, due to social and 
movement restrictions within countries, local 
distribution (street dealing) may be significantly 
impacted and altered and users’ methods to access 
drugs will change. Economic hardship may also 
reduce the disposable income of some people who 
use drugs, and result in increased crime. 
Thirdly, recent advances in the region to introduce 
community-centred elements into drug treatment 
and prevention approaches may be jeopardized. 
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An already vulnerable population of drug users 
may be exposed to additional risks as funding is 
re-prioritized, access to programmes and services 
becomes difficult, activities of treatment providers 
are hampered, and communities concentrate on 
coping with the repercussions of the COVID-19 
pandemic. 
Readers are encouraged to keep all three 
dimensions - changing trafficking and distribution 
patterns, and increased vulnerabilities - in mind 
when reading this report. 
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Overview of the 
methamphetamine market 
The methamphetamine market in East and 
Southeast Asia has been expanding continuously 
over the last decade, driven by an unprecedented 
supply of the drug. The growth in supply has led 
to decreases in prices of methamphetamine 
throughout the region, increasing its affordability 
and, likely, demand, as indicated by increasing 
numbers of drug users brought into formal contact 
with authorities. This development is posing serious 
challenges for criminal justice and public health in 
the region. 
The manufacture of methamphetamine 
has been further consolidated to the lower 
Mekong region, in particular to the Golden 
Triangle
The growing signs of an intensification of 
methamphetamine manufacturing activity within 
and around the Golden Triangle, including countries 
like Cambodia and Viet Nam, and a corresponding 
decrease in the number of methamphetamine 
manufacturing facilities dismantled in East 
and maritime Southeast Asia indicates that 
methamphetamine manufacture is now being 
consolidated in the lower Mekong region. 
In recent years, the Golden Triangle has become 
the epicentre for the illicit manufacture of 
methamphetamine in East and Southeast Asia, 
which reaches markets as far as Australia and 
New Zealand. The area has long been known for 
manufacturing large volumes of illicit drugs, mainly 
heroin and methamphetamine tablets, and has 
recently shifted towards producing increasing 
amounts of crystalline methamphetamine and 
other synthetic drugs, including ketamine. This shift 
in the Golden Triangle has been observed since late 
2015 when Myanmar authorities started seizing 
substantial quantities of these synthetic drugs.1 
With the surge in methamphetamine manufactured 
in and trafficked from the Golden Triangle, the 
Government of Myanmar has intensified its 
responses, leading to successful dismantling 
of several methamphetamine and heroin 
manufacturing facilities of an unprecedented scale. 
Between 2018 and 2019, a total of 14 clandestine 
drug laboratories were seized in Myanmar, which 
is a significant development compared to 2017 
when no manufacturing sites were dismantled.2 Of 
interest is one trafficking case reported in July 2019 
in Kayah State, where authorities seized 500 kg of 
crystalline methamphetamine, 649 kg of ketamine 
and 1,150 kg of concentrated caffeine, a typical 
bulking agent for methamphetamine tablets3, 
which may indicate possible methamphetamine 
sites outside Shan State.
In 2019, seizures of methamphetamine 
manufacturing sites were also reported in other 
lower Mekong countries. In July, authorities in Viet 
Nam dismantled the largest ever methamphetamine 
manufacturing facility in Kon Tum province, located 
near the border with Cambodia and Lao PDR.4 
20 tons of laboratory equipment and 13 tons of 
various chemicals, including more than 1,050 litres 
of P-2-P, 14 litres of benzyl cyanide, and 213 kg of 
tartaric acid, were found at the site.5 
1    For more information, see the Myanmar country chapter in the 
report. 
2    The Central Committee for Drug Abuse Control (CCDAC) of 
Myanmar, “2019 Precursor Situation in Myanmar”, presented 
at the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020.
3    CCDAC, “Drug trends and precursor control in Myanmar”, 
presented at the 43rd Meeting of Heads of National Drug Law 
Enforcement Agencies, Asia and the Pacific (HONLAP), Bangkok, 
Thailand, October 2019.
4  Standing Office on Drugs and Crime (SODC) of Viet Nam, 
“Precursor chemical control in Viet Nam”, presented at 
the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020. 
5  Ibid.
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For the first time since 2015, a synthetic drug 
refinery was dismantled in Phnom Penh, Cambodia 
in April 2019, resulting in seizures of 18 kg of 
methamphetamine, 52 kg of ketamine, 80 kg of 
MDMA, all in powder form, as well as 173 kg of 
pyrovalerone, tableting moulds and laboratory 
equipment.8
In China, the number of clandestine 
methamphetamine laboratories dismantled 
decreased from 526 in 2015 and to 85 in 2018, 
the latest year available.9 Although amounts of 
methamphetamine manufactured in and trafficked 
from China appear to have significantly decreased 
in recent years, Chinese authorities continued 
to dismantle clandestine methamphetamine 
laboratories in 2019. For instance, in November, 
Chinese authorities dismantled a total of four 
methamphetamine manufacturing facilities and 
6    Office of the Commander-in-chief of Defence Services, “More 
narcotic drugs, related materials used in drug production seized 
in Lwekham Village, Kutkai Township”, March 2020.  
7    Ibid. 
8    National Authority for Combating Drugs (NACD) of Cambodia, 
“Precursor chemical control in Cambodia”, presented at 
the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020; DAINAP.  
9    UNODC, responses to the annual report questionnaire.
Largest ever methamphetamine manufacturing sites dismantled in the Golden Triangle
The Government of Myanmar conducted a 
series of operations in North Shan, Myanmar 
throughout early 2020. As of 14 March, Myanmar 
authorities dismantled several methamphetamine 
manufacturing sites and warehouses leading to 
seizures of over 143 million methamphetamine 
tablets, which is more than the entire amount 
seized in the country in 2019, as well as 441 kg of crystalline methamphetamine.6 In addition, 246 
different types of chemicals and laboratory equipment were also seized during the operations.7 The 
case demonstrates the sheer scale of methamphetamine manufacturing capacity in the Golden Triangle.
Note: Boundaries, names and designations used do not imply 
official endorsement or acceptance by the United Nations. 
Map 1. Locations of methamphetamine manufacturing 
facilities dismantled in Myanmar, between February 
and March 2020 
three warehouses containing precursor chemicals 
in multiple provinces, including Fujian, and seized 
450 kg of ephedrine and more than 77 tons of other 
chemicals.10  Some of the dismantled laboratories 
were used for the illicit manufacture of ephedrine 
and 2-bromopropiophenone, a precursor for 
ephedrine. The National Narcotics Control 
Commission (NNCC) of China noted that organized 
crime groups based in Fujian province, remain 
active in the illicit trade of drugs and chemicals.11
There are also indications that the level of illicit 
manufacture of methamphetamine in maritime 
Southeast Asian countries may be decreasing. For 
instance, there was no seizure of methamphetamine 
laboratories in the Philippines in 2019, which is a 
first for the country in recent years. Additionally, 
in 2019, the number of methamphetamine 
laboratories dismantled respectively in Indonesia 
and Malaysia was the lowest since 2014.12 
10  NNCC, China, “Seven Provinces Jointly Solved “9 · 25” 
Extraordinary Drug Manufacturing cases”, official press release, 
November 2019 (accessed at http://www.nncc626.com/2019-
11/14/c_1210353398.htm).
11  Ibid.  
12  DAINAP.
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Figure 1. Number of methamphetamine manufacturing 
facilities dismantled in Indonesia, Malaysia, and the 
Philippines, 2014-2019
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Note: The figures refer to all laboratories, regardless of the size 
of the facility or the scale of the output. At present, there is 
no comprehensive data to assess the scale of the dismantled 
manufacturing facilities.
Source: DAINAP. 
The consolidation of methamphetamine manufacture 
in the lower Mekong region increases the challenges 
for Governments to respond to this development 
as it takes place in an area where some countries 
are lacking vital institutional capacity and resources, 
which makes them comparatively attractive target for 
organized crime groups.  
Seizures of methamphetamine in East and 
Southeast Asia have reached record levels 
every year over the last decade 
Countries in East and Southeast Asia have 
collectively witnessed sustained increases in 
seizures of methamphetamine over the last 
decade, more than any other part of the world. The 
observed seizure trends and decreases in prices of 
the drug (see page 18 of the chapter) indicate that 
the greater availability of methamphetamine in the 
market has been a major factor for the increases in 
seizures. 
While the annual seizures of methamphetamine 
have increased over the last 10 years, a major 
observation is the significant increase in the rate of 
seizures in the latter part of the decade. Between 
2011 and 2014, seizures of methamphetamine 
almost doubled, increasing from 23 to 44 tons. 
In the following years, however, seizures of 
methamphetamine almost tripled and increased 
by more than 60 tons between 2015 and 2018, 
reaching more than 127 tons of the drug in 2018. 
At the time of writing, countries in the region have 
already confirmed seizures of 115 tons of the drug 
in 2019. It should be noted that the figure does 
not yet include any data from China, which seized 
nearly 30 tons on average over the last five years. It 
is probable that the 2019 total will be higher than 
2018.13 
The steep increase in seizures of methamphetamine 
in recent years has been primarily driven by 
Southeast Asia, which increased its share of the 
regional total in East and Southeast Asia from 40 
per cent in 2011 to 80 per cent in 2018, further 
illustrating the geographic shift described above. 
Organized crime groups in the Golden 
Triangle have intensified supply of crystalline 
methamphetamine 
 
One of the major developments observed in the 
methamphetamine market in East and Southeast 
Asia is the increase in supply of methamphetamine 
in crystalline form, particularly in Southeast Asia, 
13      At the time of writing, Brunei Darussalam, Cambodia, 
Indonesia (preliminary), Japan (preliminary), Hong Kong, China 
(preliminary), Lao People’s Democratic Republic (PDR), Malaysia, 
Myanmar, the Philippines, the Republic of Korea, Singapore, 
Thailand, Taiwan Province of China, and Viet Nam (preliminary) 
have provided the drug seizure data for all of 2019. No data 
was available for China, including Macau, China, the Democratic 
People’s Republic of Korea, Mongolia, and Timor Leste for 2019.  
Figure 2. Seizures of methamphetamine in East and 
Southeast Asia, 2011-2019*  
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Note: * Data for 2019 include only those confirmed by countries 
in the region. For more information, see footnote 13 of the 
report. 
Source: UNODC, responses to the annual report questionnaire; 
Official communication with the Supreme Prosecutors’ Office 
(SPO) of the Republic of Korea, February 2020; National Police 
Agency (NPA) of Japan, “Drug Control in Japan”, presented 
at the 25th Asia-Pacific Operational Drug Enforcement 
Conference, Tokyo, Japan, February 2020; Comparison of 2019 
and 2018 crime situation, Hong Kong Police Force, (accessed at 
https://www.police.gov.hk/info/doc/overcrim.pdf). 
8Synthetic Drugs in East and Southeast Asia
which has been more pronounced and persistent 
compared to methamphetamine in tablet form. 
While in 2019, seizures of methamphetamine 
tablets in Southeast Asia decreased for the first time 
in years, by a fifth, from 647 million to 511 million 
tablets, seizures of crystalline methamphetamine 
continued to increase in 2019. Preliminary data 
show that at least 63 tons of the drug were seized 
in that year, more than a 50 per cent increase 
compared to 2018. 
For a better understanding of the methamphetamine 
tablet trends, it is necessary to take into account 
trafficking from Myanmar to South Asia, which 
has evolved into an important destination for 
methamphetamine tablets outside the Mekong 
region. While seizures of methamphetamine tablets 
in Bangladesh in 2019 decreased by 42 per cent 
to 31 million tablets compared to the preceding 
year, after several years of continuous increases,14 
India reported a substantial increase in seizures 
of amphetamine-type stimulants (ATS), up from 
431kg in 2018 to more than 2.2 tons in 2019. This 
could, at least partially, be the consequence of the 
emergence of a new trafficking route from Myanmar 
through India’s border for trafficking to Bangladesh. 
However, more information on the type of ATS seized 
and seizure locations will be needed to interpret 
these trends.15   
14  Department of Narcotics Control of Bangladesh (DNC), “Drug 
control in Bangladesh”, presented at the Meeting of Drug and 
Precursor Intelligence Specialists, Mandalay, Myanmar, February 
2020.
15  Narcotics Control Bureau (NCB) of India, “Country briefing” 
presented at the Meeting of Drug and Precursor Intelligence 
Specialists, Mandalay, Myanmar, February 2020; Data for 2019 
are preliminary according to the NCB. 
Figure 4. Seizures of methamphetamine tablets in 
Bangladesh, 2014-2019 
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Source: Department of Narcotics Control of Bangladesh (DNC). 
At this point in time, it is uncertain what the 
main driver for the increased supply of crystalline 
methamphetamine from the Golden Triangle 
would be, and whether the trend will continue. 
According to UNODC’s latest assessment, the 
methamphetamine market in East and Southeast 
Asia and neighbouring countries is as large as US$ 
61.4 billion annually.16 
Figure 5. Retail prices of crystalline methamphetamine 
per 1 gram among selected countries in East and 
Southeast Asia, Australia and New Zealand for 2019 or 
latest year available 
0
100
200
300
400
500
600
Pr
ice
s i
n 
US
$
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; National Drug Intelligence Bureau of New Zealand 
(NDIB), “Illicit Drug Pricing Report”, February 2020; Official 
communication SPO of the Republic of Korea, February 2020; 
NPA of Japan, “Drug Control in Japan”, presented at the 25th 
Asia-Pacific Operational Drug Enforcement Conference, Tokyo, 
Japan, February 2020.  
16  UNODC, “Transnational Organized Crime in Southeast Asia: 
Evolution, Growth and Impact”, July 2019.
Figure 3. Changes in methamphetamine tablet and 
crystalline methamphetamine seizures in Southeast 
Asia, 2014-2019*
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Note: * Data for 2019 are preliminary and subject to change. 
For more information, see footnote 13 of the report. 
Source: UNODC, responses to the annual report questionnaire; 
DAINAP. 
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17 18 19 20  21 22
17  DNC, “Drug Control in Bangladesh”, presented at the Meeting of 
Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, 
February 2020.
18  For instance, in September 2019, Indian authorities seized 1,156 
kg of crystalline methamphetamine in Nicobar Island, located 
at the juncture of the Bay of Bengal and the Andaman Sea. The 
drug was destined from Malaysia and Thailand, and concealed 
in distinctive teabag packaging used in the Golden Triangle; 
Narcotics Control Bureau (NCB), India, “Country briefing on drug 
and precursor situation in India”, presented at the Meeting of 
Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, 
February 2020.  
19  For more information, see the ketamine section in the report (p. 
28).
20  Royal Malaysian Police, National Anti-Drug Agency (NADA), and 
the Ministry of Health of Malaysia, “Country briefing” presented 
at the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020.
21  Official communication with CCDAC on seizures of precursor 
chemicals during the 1511 Operation, March 2020. 
22  Royal Malaysian Police, National Anti-Drug Agency (NADA), and 
the Ministry of Health of Malaysia, “Country briefing” presented 
at the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020. 
The impact of the East and Southeast Asian 
methamphetamine market expansion on 
South Asia 
Amidst growing connectivity within Asia, the 
impact of the expanding synthetic market 
in East and Southeast Asia has affected 
neighbouring South Asia. Substantial quantities 
of methamphetamine from Southeast Asia have 
been seized in South Asia. While trafficking 
flows of methamphetamine tablets from the 
Golden Triangle to Bangladesh continue to be 
observed, India has also reported increased 
seizures of ATS, most of which are suspected 
to be methamphetamine, in recent years. Two 
explanations have been suggested by experts: 
first, a growth in trafficking of methamphetamine 
tablets from the Golden Triangle overland to 
Bangladesh, with some routes crossing India.17 
Secondly, the use of a maritime trafficking routes 
from Myanmar along the Andaman Sea, some of 
which cross Indian territorial waters.18   Meanwhile, 
methamphetamine precursor chemicals and 
ketamine19 trafficked from or via South Asia to 
Southeast Asia have also been observed.20  
Figure 6. Number of cases and seizures of ATS in India, 
2017-2019* 
 
Note: Data for 2019 are preliminary and subject to change. 
Source: Narcotics Control Bureau (NCB), India, “Country 
briefing on drug and precursor situation in India”, presented 
at the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020.  
There has been a significant reduction in the 
amount of pseudoephedrine, mainly in the form of 
pharmaceutical preparations (see Figure 9) seized 
in Myanmar.21 However, the  large quantities of 
solvents like sulphuric acid seized during special 
operations conducted in northern Shan State 
in March 2020 and believed to originate from 
India, confirmed continuing flows of chemicals 
from India to Myanmar.  In addition, Malaysian 
authorities seized 200 kg of pseudoephedrine 
shipped from Bangladesh en route to Australia in 
November 2019.22 
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Organized crime groups have shifted major 
methamphetamine trafficking routes in 
response to law enforcement operations 
In 2019, there were major shifts in trafficking routes 
of crystalline methamphetamine observed across 
the region, demonstrating agility and flexibility 
of organized crime in response to intensified law 
enforcement operations in 2018. 
In Myanmar, almost all crystalline 
methamphetamine (98.2 per cent) were seized 
in Shan State in 2018, which was also the case 
in 2017.23 However, in 2019, while Shan State 
continued to account for the largest amount of 
crystalline methamphetamine seizures (4,167 kg), 
one-third of the 2019 total (3,145 kg) was seized 
23  UNODC, “Transnational Organized Crime in Southeast Asia: 
Evolution, Growth and Impact”, July 2019.
10
Synthetic Drugs in East and Southeast Asia
in Tanintharyi Region, located in the southern 
part of the country.24 In 2018, Tanintharyi Region 
accounted for merely 0.1 per cent of the total 
seizures, amounting to just 3.5 kg.25  
This shift corroborates with sub-national seizure 
data reported from Thailand and indicates that a 
new trafficking route from the Golden Triangle to 
the western border of Thailand has emerged. In 
2019, western and central provinces of Thailand, 
such as Bangkok, Pathum Thani and Tak, were 
listed in the top five provinces for crystalline 
methamphetamine seizures.26 In 2018, a large 
majority of the drug was seized in northern and 
southern provinces of the country, such as Chiang 
Rai and Chumphon, showing direct trafficking flows 
through the northern border to the southern border. 
Interestingly, there was no significant changes 
observed in entry points of methamphetamine 
tablet trafficked from the Golden Triangle to 
Thailand between 2018 and 2019.27 The disparity 
is likely due to different organized crime groups 
financing trafficking in the two drug types and their 
intended destinations.    
Thailand remains a major transit for crystalline 
methamphetamine trafficked to Oceania. For 
instance, in June 2019, Australian authorities 
reportedly seized 1.6 tons of crystalline 
methamphetamine trafficked via Bangkok, 
Thailand 28, the largest ever reported by Australia.29 
In September 2019, New Zealand authorities also 
seized 452 kg of crystalline methamphetamine 
trafficked via Bangkok, Thailand, the largest amount 
ever seized at its border.30 
24  Official communication with CCDAC, Myanmar, February 2019 
and March 2020.
25  Ibid. 
26  Official communication with ONCB, Thailand, February 2020.   
27  For instance, four provinces in Thailand, Chiang Rai, Chiang Mai, 
Bangkok and Lampang were listed in the top five provinces for 
methamphetamine tablet seizures in 2018 and 2019; Official 
communication with ONCB, February 2020 and ONCB “Synthetic 
drug situation in Thailand”, presented at the 2019 SMART 
Regional Workshop, Singapore, August 2019 
28  Australian Federal Police (AFP), “Authorities make largest ever 
onshore ice seizure”, official press release, June 2019 (accessed 
at https://www.afp.gov.au/news-media/media-releases/
authorities-make-largest-ever-onshore-ice-seizure). 
29  Ibid.  
30  New Zealand Customs Service, “Customs’ biggest 
methamphetamine seizure”, official press release, September 
2019 (accessed at https://www.customs.govt.nz/about-us/
news/media-releases/customs-biggest-methamphetamine-
seizure/). 
Map 2. Proportion of crystalline methamphetamine 
seizures in Myanmar by State and Region, 2019 
Note: Figures are rounded to the first decimal place; the sum of 
figures for each 2018 and 2019 does not add up to 100, as data 
for States or Regions with marginal seizures are not included. 
Boundaries, names and designations used do not imply official 
endorsement or acceptance by the United Nations.  
Source: Official communication with CCDAC, Myanmar, 
February 2019 and March 2020. 
Both Lao PDR and Viet Nam reported 
substantial increases in seizures of crystalline 
methamphetamine in 2019. The increases 
demonstrate that both countries have become new 
major gateways for trafficking of the drug. There 
were no crystalline methamphetamine trafficking 
cases involving more than 100 kg of the drug in 
Viet Nam prior to late 2018 and this changed in 
2019, indicating intensified flows of the drug to 
the country likely due to the change in trafficking 
routes.31 In addition,  authorities noted that a vast 
majority of crystalline methamphetamine seized in 
the country in 2019 was trafficked from the Golden 
31  SODC, “Latest situation on synthetic drugs and responses to the 
threats in Viet Nam” presented at the 2019 Regional SMART 
Workshop for East and Southeast Asia, Singapore, August 2019. 
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Map 3. Top five provinces of crystalline methamphetamine seizures in Thailand in 2018 and 2019 
Note: Boundaries, names and designations used do not imply official endorsement or acceptance by the United Nations.  
Source: Official communication with ONCB, Thailand, February 2020.   
Triangle via Lao PDR for subsequent trafficking to 
other destinations, including China, the Philippines 
and Taiwan Province of China.32  
Figure 7. Seizures of methamphetamine in Lao PDR and 
Viet Nam, 2018 and 2019 
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Source: DAINAP; Official communication with Lao PDR and Viet 
Nam, February 2020. 
32  Ibid. 
Several crystalline methamphetamine trafficking 
cases reported from the Philippines in 2019 also 
show the role of Viet Nam as a major transit point 
for drugs trafficked from the Golden Triangle. For 
instance, in March 2019, Philippine authorities seized 
276 kg of crystalline methamphetamine trafficked 
via Ho Chi Minh City, Viet Nam.33 A trade company 
established in Viet Nam by an organized crime group 
was used to ship the drug from the Philippines 
and destined to Taiwan Province of China.34 
Furthermore, there are growing indications that 
the coastal province of Sihanoukville, Cambodia, 
is gaining importance as a transhipment point for 
regional and inter-regional methamphetamine 
trafficking. According to Cambodian authorities, 
33  Dangerous Drugs Board (DDB) and Philippines Drug 
Enforcement Agency (PDEA), “Latest situation on synthetic 
drugs and responses to the threats in Philippines”, presented 
at the Regional SMART Workshop for East and Southeast Asia, 
Singapore, August 2019.   
34  SODC, “Latest situation on synthetic drugs and responses to the 
threats in Viet Nam” presented at the 2019 Regional SMART 
Workshop for East and Southeast Asia, Singapore, August 2019.
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Trafficking of methamphetamine to Australia 
and New Zealand and its impact on the 
Pacific  
For years, organized crime groups have exploited 
Pacific island countries and territories (PICTs) 
as a transhipment point for methamphetamine 
trafficked from East and Southeast Asia and 
North America to Australia and New Zealand.35 
PICTs are also increasingly targeted as destination 
markets and for the illicit manufacture of 
methamphetamine.36 This is a worrying yet 
anticipated trend, as there have been many 
instances of growing illicit drug markets in 
countries located along major drug trafficking 
routes.     
The number of drug-related offences in Fiji had 
increased by more than 560 per cent between 
2013 and 2018. Fiji authorities also noted that 
seizures of parcel posts containing illicit drugs, 
including methamphetamine, and originating 
from China, the United States and South American 
countries, had increased substantially during 
the same period.37 Tonga is another country 
that has been seriously impacted by increased 
flows of methamphetamine in recent years. In 
response, a task force specialising in illicit drugs 
was established in April 2018, and has led to 
seizures of 33.8 kg of methamphetamine and 2.4 
kg of cocaine, as of August 2019. The amount of 
methamphetamine seized in Tonga is substantial 
considering that the size of the population is 
estimated to be around 103,020.38
Figure 8. Number of drug-related offences in Fiji     
Source: Crime statistics, Fiji Bureau of Statistics (accessed 
at https://www.statsfiji.gov.fj/index.php/statistics/other-
statistics/crimes-offences); Fiji Police Force, “Fiji’s Drug 
Trend”, presented 43rd meeting of the Heads of National 
Drug Law Enforcement Agencies, Asia and the Pacific 
(HONLAP), Bangkok, Thailand, October 2019. 
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crystalline methamphetamine has been trafficked 
by sea from the Sihanoukville port to countries such 
as the Philippines and Australia.39 In addition, in 
March 2020, Thai authorities seized more than 600 
kg of the drug in several islands of Trat Province,40 
located at the far east region of Thailand, believed 
to be destined for Sihanoukville for onward 
trafficking. 
35  36 37 38 39 40 
Maritime drug trafficking remained active 
throughout 2019, in particular along Andaman 
Sea and Malacca Strait, to reach crystalline 
methamphetamine markets in Indonesia and 
35  UNODC, Transnational Organized Crime in the Pacific: A Threat 
Assessment, July 2016.
36  State Services in French Polynesia, “ICE: A long fight ahead of 
us”, official press release, January 2019 (accessed at http://
www.polynesie-francaise.pref.gouv.fr/Actualites/Communiques-
de-presse/2019/20-janvier-ICE-un-long-combat-devant-nous). 
37  Fiji Police Force, “Fiji’s Drug Trend”, presented at the 43rd 
HONLAP, Bangkok, Thailand, October 2019.
38  World Bank, Population data for Tonga (accessed at https://
data.worldbank.org/indicator/SP.POP.TOTL?locations=TO). 
39  NACD, “Precursor chemical control in Cambodia”, presented 
at the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020.  
40  Official communication with ONCB, March 2020. 
Malaysia as well as onward trafficking to Australia and 
Japan. Seizures reported in early 2020 indicate new 
maritime trafficking routes. For instance, in January 
2020, Myanmar authorities seized about 200 kg of 
crystalline methamphetamine together with 490 kg 
of ketamine on a fishing vessel leaving from Maung 
Taw, Rakhine State.41 While the departure point 
has been used for trafficking in methamphetamine 
tablets to Bangladesh, it is an unusual departure 
point for crystalline methamphetamine as there 
was no reported seizures of this particular drug 
form in Rakhine state between 2018 and 2019.42 In 
addition, there have been increasing amounts of 
crystalline methamphetamine being trafficked to 
South Kalimantan since early 2020.43 For instance, 
Indonesia authorities reported to have seized 200 kg 
of the drug together with 14 kg of “ecstasy” in the 
area in March 2020.44 
41  CCDAC, “Current situation and trafficking trends in Myanmar”, 
presented at the 25th Asia-Pacific Operational Drug Enforcement 
Conference (ADEC), Tokyo, Japan, February 2020.  
42  Official communication with CCDAC, March 2020. 
43  Indonesian National Police (INP), “Country briefing”, presented 
at the Virtual Western Maritime Route Forum on Drug 
Trafficking: Enhancing Inter-Agency Coordination, March 2020. 
44  Ibid. 
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Map 4. Methamphetamine tablet trafficking flows in the Mekong region, 2019 
Note: Flows arrows represent the general direction of trafficking and do not coincide with precise sources of production or 
manufacture, are not actual routes, and are not weighed for significant/scale. Boundaries, names and designations used do not 
imply official endorsement or acceptance by the United Nations.
Source: UNODC elaboration based on information presented at the 2019 SMART Regional Workshop, Singapore, August 2019 and 
the Meeting of Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, February 2020.  
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Map 5. Crystalline methamphetamine trafficking flows in East and Southeast Asia, 2019 
 
Note: Flows arrows represent the general direction of trafficking and do not coincide with precise sources of production or 
manufacture, are not actual routes, and are not weighed for significant/scale. Boundaries, names and designations used do not 
imply official endorsement or acceptance by the United Nations.
Source: UNODC elaboration based on information presented at the 2019 SMART Regional Workshop, Singapore, August 2019 and 
the Meeting of Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, February 2020.  
East and Southeast Asia has not been 
successfully curbing diversion of and 
trafficking in precursor chemicals
The manufacture of methamphetamine requires 
key precursor chemicals, such as ephedrine, 
pseudoephedrine, and P-2-P.45  In East and 
Southeast Asia, growing methamphetamine 
manufacture would not be possible without a 
matching surge in precursor chemical diversion 
and trafficking. However, recent seizure trends 
of methamphetamine precursor chemicals 
are not commensurate with the trends in 
methamphetamine seizures, and might be 
45  Ephedrine, pseudoephedrine and P-2-P are listed in Table I of 
the United Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988.
indicative of difficulties in coping with increasing 
diversion, trafficking and the illicit manufacture of 
those key precursor chemicals.
As the Golden Triangle has been the major 
methamphetamine manufacture centre in East 
and Southeast Asia, it is important to identify and 
monitor trends and types of precursor chemical 
trafficking destined to Myanmar. Since 2015, 
seizures of ephedrine and pseudoephedrine have 
decreased significantly in Myanmar. There has 
been no recent seizure of pseudoephedrine and 
only 4 kg of ephedrine were seized in 2019 in the 
country. At the same time, seizures of P-2-P have 
greatly fluctuated with only insignificant amounts 
(300 lt) of the chemical seized in 2019. 
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Excluding Myanmar and Viet Nam, only three other 
countries in Southeast Asia, Indonesia, Malaysia 
and the Philippines, reported to have seized either 
ephedrine, pseudoephedrine or P-2-P in 2019. 
However, the amounts seized in these countries 
were very small,46 and is illustrative of the increasing 
challenges in detecting methamphetamine related 
precursor chemicals in the region and beyond.47   
A vast majority of recent seizures reported by the 
Myanmar authorities point to areas bordering 
China, as being heavily exploited by transnational 
organized crime groups for precursor trafficking.48 
To stop flows of precursors to Myanmar, the 
Government of China has intensified its law 
enforcement efforts. Between January to early 
October 2019, Chinese authorities seized a total of 
873.4 tons of various illicit drug making materials, 
including precursor chemicals and auxiliaries along 
all border check points in Yunnan province of China, 
bordering Myanmar.49 Another entry point for 
chemicals to Myanmar is Tachileik, in the southern 
Shan State on the border with Thailand, where 
large quantities of hydrochloric acid and sodium 
46  For instance, Malaysia reported to have seized 200 kg of 
pseudoephedrine and 12 kg of ephedrine while only 46 g and 
76.8 g of ephedrine were seized respectively in Indonesia and in 
the Philippines. Data for Indonesia for 2019 are preliminary and 
subject to change.  
47  See also UNODC, An expanding synthetic drugs market - 
implications for precursor control, Global SMART Update, Vol. 
23, March 2020.
48  CCDAC, “2019 Precursor Situation in Myanmar”, at the Meeting 
of Drug and Precursor Intelligence Specialists, Mandalay, 
Myanmar, February 2020.
49  NNCC, China, “Yunnan Entry-Exit Border Inspection Station 
Commends Advanced Groups and Individuals”, official press 
release, November 2019. 
cyanide50 have been seized in recent years.51 
The types of chemicals seized in Myanmar in 
recent years point to new synthesis methods being 
used for the manufacture of methamphetamine. 
Since 2017, increasing quantities of sodium 
cyanide and, very recently, benzyl cyanide, have 
been seized in Myanmar and Thailand en route 
to the Golden Triangle.52 Myanmar authorities 
reported significant amount of seizures of about 
8,000 lt of benzyl cyanide and more than 12 tons 
of sodium ethoxide in separate incidents during 
the first quarter of 2020,53  both of which can be 
also used for synthesizing P-2-P. It may not be a 
coincidence that seizures of such chemicals have 
increased over the past few years when the region 
started witnessing a surge of methamphetamine 
manufactured in the Golden Triangle, indicating the 
growing sophistication and flexibility of organized 
crime groups in using non-traditional chemicals to 
engineer the expansion of the market. 
50  A combination of benzyl chloride and sodium cyanide is 
required for the synthesis of benzyl cyanide and subsequently 
P-2-P. The absence of seizures of benzyl chloride makes it 
difficult to determine if the sodium cyanide seized in recent 
years is intended as precursors for the production of P-2-P.
51  CCDAC, “2019 Precursor Situation in Myanmar”, at the Meeting 
of Drug and Precursor Intelligence Specialists, Mandalay, 
Myanmar, February 2020.
52  Sodium cyanide and benzyl cyanide are not listed as controlled 
substances under the 1988 UN Convention Against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances, and both these 
substances can be used to synthesize P-2-P.
53  CCDAC, “2019 Precursor Situation in Myanmar”, at the Meeting 
of Drug and Precursor Intelligence Specialists, Mandalay, 
Myanmar, February 2020.
Figure 9. Seizures of ephedrine, pseudoephedrine, and P-2-P in Myanmar, 2015-2019  
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Note: The amount of pseudoephedrine found in tablets varies. 
Source: DAINAP; CCDAC, “2019 Precursor Situation in Myanmar”, at the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020.
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Substantial quantities of chemicals have been 
seized in Lao PDR en route to the Golden Triangle. 
In 2019, 13.4 tons of chemicals, by far the largest 
amount on record, were seized in the country.54 A 
vast majority of the total was due to a case reported 
in May 2019, involving 10 tons of an unspecified 
chemical seized in Bokeo province destined for the 
Golden Triangle.55 In addition, in November 2019, 
Lao PDR authorities reported to have seized 13 kg 
of methylamine, a chemical that can be used for 
the manufacture of a number of synthetic drugs, as 
well as ephedrine.56 
There are indications that precursor chemicals 
being increasingly diverted and trafficked from and 
within Viet Nam. A large-scale methamphetamine 
laboratory dismantled in September 2019 resulted 
in seizures of more than 13 tons of various chemicals, 
including P-2-P. Viet Nam authorities reported that 
seized chemicals were known to have been diverted 
within the country.57 Countries in Europe  noted 
seizures of alpha-phenylacetoacetonitrile (APAAN), 
a designer precursor chemical for P-2-P, which 
either originated from or transited through Viet 
Nam between 2018 and 2019.58    
Recent information on methamphetamine profiling 
reported from countries in the region indicate 
the increased use of P-2-P methods for the 
manufacture of methamphetamine. For instance, 
China reported that 25 per cent of crystalline 
methamphetamine samples analysed in 2018 
were manufactured with the reductive animation 
method, which uses P-2-P as a key precursor 
chemical while the corresponding figure for 2017 
was only 2 per cent.59 However, it is important 
to note that ephedrine and pseudoephedrine 
remain the major precursor chemicals used for 
the manufacture of methamphetamine in the 
54  DAINAP. 
55  LCDC, “Latest situation of synthetic drugs in Lao PDR”, presented 
the 2019 Regional SMART Workshop for East and Southeast 
Asia, Singapore, August 2019.
56  INCB; Official communication with the Lao PDR Customs, 
November 2019.   
57  SODC, “Country briefing”, presented at the Meeting of Drug and 
Precursor Intelligence Specialists, Mandalay, Myanmar, February 
2020.  
58  INCB, “Precursors and chemicals frequently used in the illicit 
manufacture of narcotic drugs psychotropic substances 2019”, 
February 2020.
59  NNCC, “Latest situation of synthetic drugs in China”, presented 
at the Global SMART Programme Regional Workshop, 
Singapore, August 2019.
region (see Figure 10). Despite this, seizures of 
ephedrine, pseudoephedrine and their precursors 
in the region remains extremely low in recent 
years. This mismatch in drug profiling information 
and seizure trends might be indicative of significant 
intelligences gaps and difficulties in coping with 
diversion, trafficking and the illicit manufacture of 
those key precursor chemicals.
Figure 10. Crystalline methamphetamine forensic 
profiles reported from China, Indonesia, the Philippines 
and Thailand, 2017-2019*
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Note: Data for the Philippines for 2019 are preliminary. 
Source: NNCC “Latest situation of synthetic drugs in China” 
and BNN “Latest situation of synthetic drugs in Indonesia” 
presented the 2019 Regional SMART Workshop for East and 
Southeast Asia, Singapore, August 2019; DDB & PDEA, “Country 
report”, presented at the Meeting of Drug Forensic Specialists, 
Beijing, China, December 2019; Official communication with 
ONCB, February 2020.    
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Map 6. Selected methamphetamine precursor chemical trafficking cases in Southeast Asia, 2019-2020*
Note: Boundaries, names and designations used do not imply official endorsement or acceptance by the United Nations; 
*Information reported up-to February 2020. 
Source: UNODC elaboration based on information presented at the 2019 SMART Regional Workshop, Singapore, August 2019 and 
the Meeting of Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, February 2020.  
Methamphetamine has become cheaper, 
reaching its lowest points in the last decade 
Monitoring changes in prices of illicit drugs can 
provide insights into the interaction between 
supply and demand (see Figure 11). 
The increases in annual seizures amounts of 
methamphetamine in East and Southeast Asia over 
the last decade, were accompanied by decreases in 
retail prices of methamphetamine. As the purity of 
methamphetamine products remains high and the 
limited information available on drug use trends 
does not indicate a reduction in demand, this 
development suggests a supply-driven increase in 
availability.  
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Figure 11. Major factors influencing prices of methamphetamine in East and Southeast Asia  
-  Expenses required for the 
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The latest available typical retail prices of 1 g 
of crystalline methamphetamine in East and 
Southeast Asia, Australia and New Zealand vary 
significantly.  Reported prices range from under 
US$ 20 in Myanmar and Viet Nam to US$ 562 in 
Japan (see Figure 5). Notwithstanding this, the 
decrease in retail prices can be observed among a 
large number of countries in the region, including 
Indonesia, Thailand, and Viet Nam, where retail 
prices of 1 g of crystalline methamphetamine more 
than halved over the last decade. Decreases in 
retail prices of crystalline methamphetamine were 
also observed in Australia, New Zealand, and the 
Republic of Korea, all of which have been major 
destinations for the drug manufactured in and 
trafficked from the Southeast Asia region. Retail 
prices in Australia and New Zealand have dropped 
at an even faster rate since 2015 when the steep 
surge in the manufacture of methamphetamine 
started in the Golden Triangle.   
Figure 12. Changes in typical retail prices of crystalline 
methamphetamine of selected countries in East and 
Southeast Asia, 2011, 2015 and 2019 or latest year 
available 
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Note: The high-low bars represent the upper and lower limits 
of the price range for those countries which reported such 
range in addition to the typical price; data in the table are not 
adjusted for purity. For the purpose of this figure, a mid-point 
of upper and lower limit was used when data were reported in 
a range format. 
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; Official communication with NACD of Cambodia, 
LCDC of Lao PDR, CCDAC of Myanmar, and ONCB of Thailand, 
February 2020. 
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Figure 13. Changes in typical retail prices of crystalline 
methamphetamine of Australia, New Zealand and the 
Republic of Korea, 2011, 2015 and 2019 or latest year 
available 
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Note: The high-low bars represent the upper and lower limits 
of the price range for those countries which reported such 
range in addition to the typical price; data in the table are 
not adjusted with purities. For the purpose of this figure, a 
mid-point of upper and lower limit was used when data were 
reported in a range format. 
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; NDIB, “Illicit Drug Pricing Report”, February 2020; 
Official communication with SPO, February 2020. 
The four countries in the Mekong region, Cambodia, 
Lao PDR, Myanmar and Thailand, which account 
for the vast majority of annual methamphetamine 
tablet seizures in Southeast Asia every year, 
reported sharp decreases in typical retail prices 
of the drug over the last decade. In Thailand, the 
reported price for a methamphetamine tablet 
in 2019 was at US$ 2.5, marking a 70 per cent 
decrease compared to 2011 (US$ 8.2).60   
A similar trend is also observed in Myanmar where 
the retail price of the drug has more than halved 
from US$ 5 to US$ 2.61 In Lao PDR, the average price 
for a methamphetamine tablet in 2019 was reported 
to be only one-third of the corresponding figure 
reported in 2011.62 Thai authorities also reported 
that the retail price of a methamphetamine tablet in 
the northern part of Thailand, the main entry point 
of the drug trafficked from the Golden Triangle, is 
as low as US$ 1.63  
60  DAINAP. 
61  Ibid.  
62  Official communication with LCDC, February 2020. 
63  Official communication with ONCB, February 2020. 
Figure 14. Changes in typical prices of methamphetamine 
tablets of selected countries in Southeast Asia, 2011, 
2015 and 2019 
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Note: The high-low bars represent the upper and lower limits 
of the price range for those countries which reported such 
range in addition to the typical price; data in the table are 
not adjusted with purities. For the purpose of this figure, a 
mid-point of upper and lower limit was used when data were 
reported in a range format.
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; Official communication with NACD of Cambodia, 
LCDC of Lao PDR, CCDAC of Myanmar, and ONCB of Thailand, 
February 2020. 
While prices of the drug have decreased, purities 
of methamphetamine have been stable in several 
countries, including Brunei Darussalam and 
China, or even increased in a select few cases. 
For instance, almost all (99 percent) crystalline 
methamphetamine samples analysed in Thailand 
in 2019 had purities over 90 per cent (on average 
94.9 per cent), while average purities of the drug 
reported in 2011 and 2015 were 90 per cent.64 
Typical purities of crystalline methamphetamine 
analysed in Indonesia and Malaysia in 2019 also 
show increases in relation to the purities reported 
in 2011.65 
Simply put, organized crime groups have been 
able to provide better quality methamphetamine 
products with cheaper price tags, indicating 
reduced cost of manufacturing the drug. All in all, 
tablet and crystalline methamphetamine prices in 
several countries in the region have reached their 
lowest points over the last decade despite a record 
number of seizures made every year during the 
same period. It indicates that the current level of 
methamphetamine seizures does not seem to have 
much impact on the availability of the drug in the 
market as reflected in price and purity data.  
64  UNODC, responses to the annual report questionnaire; Official 
communication with ONCB, April 2020.
65  UNODC, responses to the annual report questionnaire; DAINAP. 
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As prices of methamphetamine get cheaper, 
use and affordability of the drug increase
As methamphetamine becomes cheaper in East and 
Southeast Asia, it may have an impact on changes in 
the total number of methamphetamine users and 
quantities of the drug consumed by existing users 
in recent years. Due to a significant lack of drug 
demand data in the region, it is difficult to assess 
changes in methamphetamine market demand. 
To assess trends in the use of methamphetamine 
and other illicit drugs and in the absence of 
representative, population-based prevalence of use 
surveys in most countries, countries in the region 
mainly rely on the number of drug users brought into 
formal contact with authorities and/or treatment 
admissions, although both indicators should be 
used with caution for that purpose. Changes in the 
number of methamphetamine related treatment 
admissions reported from several countries in 
the region show sharp increases. For instance, in 
Malaysia, the number of treatment admissions 
for the use of methamphetamine increased by 31 
times between 2011 and 2018, from 528 to 16,384 
admissions.66 The number of registered ATS users in 
Viet Nam also increased significantly from 11,140 
in 2011 to 140,000 as of the first half of 2019, and 
the surge has been highly likely due to the use of 
methamphetamine considering the drug being the 
most frequently used form of ATS in the country. 67
The decreases in prices of methamphetamine in a 
decade of economic growth with rising income levels 
have potentially increased affordability of the drug 
in East and Southeast Asia. This becomes evident 
when comparing prices for methamphetamine 
tablets, a drug typically used by people in ‘blue 
collar’ jobs68, with monthly minimum wage as a 
benchmark for their income level. In Lao PDR, the 
monthly minimum wage increased by nearly 260 
per cent over the last decade, while the typical 
price for a methamphetamine tablet decreased 
by one-third.69 In 2019, methamphetamine user in 
Lao PDR would have had to spend less than one per 
66  DAINAP. 
67  Ibid; SODC, “Synthetic drug situation in Viet Nam”, presented at 
the 2019 SMART Regional Workshop, Singapore, August 2019.
68  See UNODC, Methamphetamine continues to dominate 
synthetic drug markets. Global SMART Update, Vol. 20, Sept. 
2018. 
69  For instance, the monthly minimum wage for 2011 in Lao PDR 
was 348,000 kip while in 2019 it was 1,100,000. During the 
same period, the typical retail price for one methamphetamine 
decreased from 3 to 1 US$. 
cent of their monthly minimum wage to purchase 
one methamphetamine tablet, while in 2011, a 
tablet would cost them 9 per cent of the monthly 
minimum wage in that year.70 A similar trend can be 
observed in other lower Mekong region countries 
as well (see Figure 15). These stark changes in 
hypothetical affordability at the macro-level should 
not be interpreted as factors directly influencing 
the decision of individuals to use or not to use 
methamphetamine. However, they may serve as 
an illustration of a general picture of increasing 
availability of methamphetamine and decreasing 
barriers to affordability and therefore use, which 
falling methamphetamine prices form part of. A 
practical consequence affecting individual users is 
that some can afford to buy larger drug quantities 
in a single purchase event. If caught these 
quantities may exceed thresholds set in national 
law to differentiate between amounts intended 
for personal consumption and those indicating 
intent to supply (trafficking) – potentially leading 
to a larger number of drug users with trafficking 
offences.
Figure 15. Proportion of monthly minimum wage 
needed to purchase one methamphetamine tablet in 
Cambodia, Lao PDR, and Thailand, 2011 and 2019
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Note: Minimum wages reported in local currencies were 
converted to US$ based on average representative currency 
exchange rates for 2011 and 2019. A mid-point wage was used 
when there were more than one minimum wages for different 
industries or regions in assessed countries; This analysis does 
not take into consideration of other factors that could influence 
affordability of methamphetamine tablets for users in the 
assessed countries, such as increases in the cost of essential 
commodities and services  (i.e. rent, food and transportation). 
Source: DAINAP; Ministry of Labour and Vocational Training 
of Cambodia; Lao National Chamber of Commerce and 
Industry; Ministry of Labour of Thailand; International Labour 
Organization (ILO), Database of national labour, social security 
and related human rights legislation (NATLEX).   
70  DAINAP; Lao National Chamber of Commerce and Industry. 
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Overview of the ecstasy 
market 
The “ecstasy”71 market in East and Southeast 
Asia is fed by locally manufactured products as 
well as imported MDMA in various forms, usually 
from Europe. The market remains relatively small 
compared to the regional methamphetamine 
market, but domestic manufacture of MDMA 
appears to be spreading in the lower Mekong 
countries. Precursor chemicals for the manufacture 
of MDMA are being diverted within the region 
for domestic manufacture as well as subsequent 
trafficking to Europe.72 
Although the reported use of “ecstasy” is limited, 
the proportion of female users is generally higher 
in comparison to other major drugs consumed in 
the region, such as methamphetamine and heroin. 
There have been noticeable increases in MDMA 
contents in ecstasy tablets found in East and 
Southeast Asia in recent years. In addition, seizures 
of liquid and crystalline MDMA, perceived by drug 
users as ‘purer’ than “ecstasy” in tablet form, is 
now being reported in the region, adding further 
complexity to the regional “ecstasy” market. 
As with methamphetamine, the manufacture 
of MDMA is spreading to the lower Mekong 
region 
MDMA manufacture does not appear to be 
significant in East and Southeast Asia, however, 
there are strong indications of increased production 
in the lower Mekong region.
In April 2019, Cambodian authorities dismantled 
a laboratory in Phnom Penh and seized 80 kg of 
MDMA together with 18 kg of methamphetamine 
and 52 kg of ketamine, all in powder form. 
Moreover, 173 kg of pyrovalerone, prepared to be 
71  Ecstasy tablets sold in East and Southeast Asia may contain a 
range of substances in varying composition and quantities in 
addition or instead of MDMA. 
72   3,4-MDP-2P-methylglycidate (PMK glycidate), mainly sourced 
from China, appears to be the most widely used chemical for 
the manufacture of MDMA in Europe (European Monitoring 
Centre for Drugs and Drug Addiction and EUROPOL, “EU Drug 
Markets Report 2019”, November 2019). The substance was 
placed under international control in Table I of the Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 at the 62nd Commission on Narcotics Drugs 
held in March 2019. 
sold as “ecstasy” tablets were seized at the site.73 
Another laboratory was also dismantled in Phnom 
Penh in December, resulting in seizures of 74.8 kg 
of MDMA in crystalline and liquid form as well as 10 
kg of methamphetamine.74   
There are also indications of MDMA manufacture 
in Myanmar. For instance, in May 2019, Myanmar 
authorities seized 1,400 lt of safrole, a precursor for 
MDMA, in Shan State near the border with China.75 
In addition, China reported Myanmar as one of top 
three embarkation points for “ecstasy” trafficked to 
the country in 2018.76 
Malaysian authorities dismantled just one 
clandestine MDMA manufacturing facility in 
2019, after having dismantled a total of 33 
facilities between 2014 and 2018. Indonesia 
did not dismantle any MDMA manufacturing 
facilities in 2019, after having dismantled 8 ecstasy 
manufacturing facilities between 2014 and 2018 
and at least one in each of these reporting years.77 
These trends may possibly indicate a shift in MDMA 
manufacture from the maritime Southeast Asian 
sub-region to the lower Mekong countries.  
Figure 16. Number of MDMA manufacturing facilities 
dismantled in Cambodia, Indonesia, Malaysia, and Viet 
Nam 2014-2019 
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Source: UNODC, responses to the annual report questionnaire; 
DAINAP; Official communication with BNN, February 2020; 
Official communication with NADA, February 2020; Official 
communication with SODC, April 2020.   
73  NACD, “Precursor chemical control”, presented at the Meeting 
of Drug and Precursor Intelligence Specialists, Mandalay, 
Myanmar, February 2020. 
74  Ibid. 
75  CCDAC, “2019 Precursor Situation in Myanmar”, at the Meeting 
of Drug and Precursor Intelligence Specialists, Mandalay, 
Myanmar, February 2020.
76  UNODC, responses to the annual report questionnaire.
77  Ibid. 
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While the use of “ecstasy” remains not yet 
widespread in East and Southeast Asia, there 
are indications of increased use of the drug 
and the proportion of female users is higher 
than other major drugs 
Apart from Indonesia, none of the countries in 
East and Southeast Asia reported “ecstasy” as 
one of top three commonly used drugs in 2019 
or latest year available.78 The number of “ecstasy” 
users admitted to treatment facilities in the 
region remain insignificant compared to that of 
methamphetamine. For instance, in 2019 less than 
1 per cent of the total number of drug treatment 
admissions in the Philippines, Singapore and 
Thailand were due to the use of “ecstasy”. However, 
expert perceptions on “ecstasy” use reported from 
countries including Brunei Darussalam, Cambodia, 
Hong Kong, China, Japan, Singapore, and Viet Nam, 
indicate its increased use in recent years.79 Some 
countries in the region also reported an increase in 
the number of “ecstasy” users brought into formal 
contact with authorities in recent years, including 
Malaysia and Singapore.80 
Map 7. Perceived “ecstasy” use trends, 2019 or latest 
year available 
Increasing
Stable
Decreasing
No trend reported
Note: Based on expert perception provided by national 
authorities in East and Southeast Asia; Boundaries, names 
and designations used do not imply official endorsement or 
acceptance by the United Nations.  
Source: UNODC, responses to the annual report questionnaire; 
DAINAP. 
One notable development in the region’s “ecstasy” 
market is the high proportion of female users as 
opposed to other major illicit drugs consumed in 
the region, such as methamphetamine and heroin. 
78  DAINAP; UNODC, responses to the annual report questionnaire.
79  Ibid. 
80  For more information, see the Malaysia and Singapore country 
chapters in the report.
The underlying reason for this phenomenon is 
unclear and requires further study. 
Steep increases in seizures of “ecstasy” 
observed in several countries in East and 
Southeast Asia
In 2018, a total of 4 million “ecstasy” tablets were 
seized in East and Southeast Asia. Though it is an 
increase compared to amounts reported between 
2013 and 2016, seizures in 2018 represent a 
substantial decrease compared to 2017 when 
more than 9.2 million tablets were seized in the 
region. The sharp drop was primarily due to figures 
reported from China and Indonesia, in which 
combined seizures of “ecstasy” decreased from 
6.6 million to 1.8 million tablets between 2017 and 
2018.81 However, several countries in the region, 
including Cambodia, Hong Kong, China, Japan, 
Malaysia, the Republic of Korea, and Thailand 
reported steep increases in seizures of the drug in 
recent years.82 Based on preliminary data for 2019, 
at least 4.7 million ecstasy tablets were seized in 
East and Southeast Asia, with about 90 per cent of 
these seized by Cambodia, Indonesia, Hong Kong, 
China, and Malaysia. 
81  UNODC, responses to the annual report questionnaire.
82  For more information, see the respective country chapter in the 
report. 
Figure 17. Proportion of female “ecstasy”, 
methamphetamine and heroin related treatment 
admissions among all treatment admissions in 
Malaysia, the Philippines and Thailand, 2019* 
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Note: * Data for 2019 for Malaysia and the Philippines cover 
the first half of the year; data for Malaysia in this figure 
also include amphetamine users; heroin related treatment 
admission data for the Philippine were not included due to the 
small sample number (two admissions) reported as of the first 
half of 2019.     
Source: DAINAP; NADA, PDEA & DDB and ONCB, “Country 
briefing”, presented at the Regional SMART Workshop for East 
and Southeast Asia, Singapore, August 2019. 
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8384 85 86 87
“Ecstasy” flows from other regions, in particular 
Europe, continue to be reported in East and 
Southeast Asia. The Netherlands, Germany, 
Belgium, and France were among major 
embarkation points for “ecstasy” seized in Hong 
Kong, China, Indonesia, Myanmar, the Philippines, 
83  Australian Criminal Intelligence Commission (ACIC), National 
Wastewater Drug Monitoring Programme Report 9, March 
2020.
84  Tested substances were methamphetamine, MDMA, cocaine, 
heroin and fentanyl.
85  New Zealand Police (NZP), National Wastewater Testing 
Programme.
86  Ibid.
87  AFP, “More than one tonne of MDMA seized, five people 
charged”, press release, March 2020 (accessed at https://www.
afp.gov.au/news-media/media-releases/more-one-tonne-
mdma-seized-five-people-charged); Official communication with 
the Supreme Prosecutors’ Office of the Republic of Korea and 
Korean Customs Services, March 2020.
and the Republic of Korea in 2018.88 Trafficking flows 
of “ecstasy” from North America to the region were 
also reported by China and the Republic of Korea in 
the same year.89 Malaysia and Viet Nam reported 
that their “ecstasy” markets had also been supplied 
by domestic manufacture.90 
88  UNODC, responses to the annual report questionnaire.
89  Ibid. 
90  Ibid; SODC, “Country briefing”, presented at the Meeting of  
Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, 
February 2020. 
Latest developments in “ecstasy” markets 
in Australia and New Zealand and possible 
implications for East and Southeast Asia 
There are strong indications suggesting the rapid 
expansion of the “ecstasy” market in Australia 
and New Zealand. According to the national drug 
monitoring programme in Australia, an estimated 
2,226 kg of pure MDMA was consumed between 
July 2018 and June 2019. The figure represents 
almost a two-fold increase compared to the 
amount estimated in the preceding year (1,162 
kg).83 In New Zealand, the latest wastewater 
analysis conducted during the fourth quarter 
of 2019 shows that MDMA was the second 
most commonly detected illicit drug across the 
country84 and on average 8.2 kg of the drug was 
consumed per week (426.4 kg per year).85 This is a 
significant increase compared to the first quarter 
of 2019 when 4 kg of the drug was estimated to 
be consumed per week in the country (208 kg per 
year).86 
Although currently, MDMA manufactured in East 
and Southeast Asia does not seem to play a major 
role in supplying the expanding “ecstasy” market 
in Australia and New Zealand, these lucrative 
markets have the potential to attract the interest 
of drug trafficking syndicates in the region, 
which already command supply networks for 
methamphetamine. Indeed, a recent “ecstasy” 
trafficking case reported by Australia in March 
2020, when authorities seized 1,053 kg of MDMA 
suspected to have originated in Europe and 
trafficked via the Republic of Korea, involved a 
suspected syndicate member from Hong Kong, 
China.87 It is not unreasonable to imagine that the 
increasing sophistication achieved by syndicates 
with regard to methamphetamine manufacture 
would allow them to also produce larger amounts 
of MDMA, given the opportunities for diversion of 
its main precursors in the region. 
Figure 18. Estimated amounts of pure MDMA 
consumed in Australia between 2017-2018 and 2018-
2019 and New Zealand between the first and fourth 
quarter of 2019
  
Source: Australian Criminal Intelligence Commission, 
National Wastewater Drug Monitoring Programme Report 
9, March 2020; New Zealand Police, National Wastewater 
Testing Programme Quarter 1, April 2019, Quarter 2, August 
2019, Quarter 3, October 2019 and Quarter 4 February 2020. 
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Figure 19. Seizures of “ecstasy” in East and Southeast 
Asia, 2014-2019*
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Note: * Data for 2019 are preliminary and include only those 
confirmed or officially reported by countries in the region, and 
for more information see footnote 13 of the report; figures 
reported in units other than number of tablets were converted 
into estimated tablet equivalent at 300 mg per tablet.   
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; Official communication with SPO of the Republic of 
Korea, February 2020; National Police Agency (NPA) of Japan, 
“Drug Control in Japan”, presented at the 25th Asia-Pacific 
Operational Drug Enforcement Conference, Tokyo, Japan, 
February 2020;  Comparison of 2019 and 2018 crime situation, 
Hong Kong Police Force, (accessed at https://www.police.gov.
hk/ppp_en/09_statistics/csc_2018_2019.html).
Ecstasy has become purer and the emergence 
of crystalline MDMA is now reported in 
Southeast Asia
In recent years, there have been noticeable 
increases in the MDMA content of “ecstasy” 
tablets in several countries in East and Southeast 
Asia.91 For instance, the average MDMA content 
of “ecstasy” tablet samples analysed in Malaysia 
during the first ten months of 2019 was 50 per 
cent compared to only 30 per cent in 2018.92 In 
Cambodia, the average MDMA content of “ecstasy” 
tablet samples analysed in 2019 was 37.6 per cent, 
which is a significant increase compared to three 
preceding years.93 The Philippines also reported an 
increase in the average MDMA purity from 25.2 per 
cent in 2015 to 40 per cent in 2019.94,95   
91  Ecstasy tablets seized in different countries in East and 
Southeast Asia may differ in weights and sizes.
92  Department of Chemistry Malaysia, “Country report”, presented 
at the Meeting of Drug Forensic Specialists, Beijing, China, 
December 2019.
93  According to NACD of Cambodia, the average MDMA content 
for 2016, 2017 and 2018 were respectively 25.4, 24.9 and 30.6 
per cent; Official communication with NACD, March 2020. 
94  DDB and PDEA, “Country report”, presented at the Meeting of 
Drug Forensic Specialists, Beijing, China, December 2019.
95  Data on the absolute amount of MDMA per tablet were not 
reported from Cambodia, Malaysia and the Philippines. 
Moreover, Cambodian authorities also seized 20 kg 
of crystalline MDMA at a synthetic drug laboratory 
dismantled in Phnom Penh in April 2019.96 It is 
not yet clear, if MDMA in crystalline form is also 
sold at the street level and consumed in that 
form. However, other regions, including Oceania, 
Europe and South America, have experienced this 
phenomenon,97 which has been associated with an 
increased risk of overdose events.98 
In addition to “ecstasy” tablets and crystalline 
MDMA, drug products in liquid form containing 
MDMA in combination with other synthetic drugs 
have been found in countries in East and Southeast 
Asia. For instance, a growing concern in China is 
a drug marketed as ‘happy water’, which is sold 
in bottles containing varying amounts of MDMA, 
methamphetamine and ketamine in solution. The 
varying amount and composition of substances 
from bottle to bottle have been associated with 
an increased risk of overdose events.99 Cambodian 
authorities have also noted an increased use of 
liquid MDMA in entertainment settings.100  
Overview of the new 
psychoactive substances 
(NPS)101 market 
Beyond methamphetamine and “ecstasy”, there is 
a diversity of other synthetic drugs, including NPS, 
being consumed in East and Southeast Asia. One 
key persistent trend relates to the non-medical use 
of ketamine, which has been a major challenge 
primarily for China, including Hong Kong, China. In 
96  NACD, “Precursor chemical control”, presented at the Meeting 
of Drug and Precursor Intelligence Specialists, Mandalay, 
Myanmar, February 2020.  
97  UNODC, “Global Synthetic Drugs Assessment. Amphetamine-
type stimulants and new psychoactive substances”, 2017.
98  UNODC, “Global SMART Newsletter for Latin America and the 
Caribbean, Issue No. 3”, March 2019. 
99  NNCC, “Latest situation of synthetic drugs in China”, presented 
at the Global SMART Programme Regional Workshop, 
Singapore, August 2019.
100  NACD, “Country briefing”, presented at the Meeting of drug 
forensic specialists, Beijing, China, December 2019.
101   New psychoactive substances (NPS) are generally defined as 
substances of abuse, either in a pure form or a preparation, that 
are not controlled by the 1961 Single Convention on Narcotic 
Drugs or the 1971 Convention on Psychotropic Substances, 
but which may pose a public health threat. The term “new” 
does not necessarily refer to new inventions but to substances 
that have recently emerged on the market. For the purpose of 
this report and ease of analysis, the term “NPS” is extended to 
include also substances that have been recently scheduled in 
the 1961 or 1971 Conventions.
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recent years, countries in Southeast Asia, located 
along major trafficking routes of ketamine, are 
also witnessing its increased non-medical use. 
While most of the ketamine consumed in East and 
Southeast Asia is manufactured within the region, 
there is some supply from other parts of the world. 
Similar to North America and Europe, East and 
Southeast Asia is observing an increase in the 
number of potent synthetic opioids, including 
fentanyl analogues, reported annually. While the 
extent of non-medical use of synthetic opioids in 
the region remains unclear, their emergence can 
potentially lead to serious health harms for users 
in the region, as developments in other parts of the 
world have shown. 
The number of NPS, including potent 
synthetic opioids, reported from the region 
has increased steadily
By the end of 2019, a total of 461 different NPS were 
reported by countries in East and Southeast Asia, 
almost half of the total number reported at the 
global level.102 Japan reported the largest number 
of NPS (366 substances), followed by China (201), 
102 UNODC EWA on NPS. 
Singapore (118), and the Republic of Korea (93). 
The number of NPS detected in some countries 
in the region, including Cambodia, Lao PDR, and 
Myanmar remain limited and may, in part, be 
attributed to their limited capacity to identify these 
substances. 
By chemical substance group, synthetic 
cannabinoids account for the largest share of the 
total NPS reported with 142 different substances 
followed by synthetic cathinones (102 substances). 
Between 2018 and the first half of 2019, 5F-MDMB-
PINACA, MMB-FUBINACA, and 5F-MDMB-PICA 
were reported as the most frequently identified 
substances by several counties in the region, 
including China, Singapore, and Viet Nam.103 During 
the same period, several synthetic cathinones, 
including N-ethylpentylone and β-keto-N,N-
dimethylbenzodioxolylbutanamine (dibutylone) 
were also frequently identified.104 In terms of the 
pharmacological effects, the majority of substances 
reported have stimulant effects, followed by 
synthetic cannabinoid receptor agonists and 
hallucinogens. 
103 Country reports presented by at the Regional SMART workshop 
for East and Southeast Asia, Singapore, August 2019. 
104 Ibid. 
Figure 20. Emergence of NPS in East and Southeast Asia, up to December 2019* 
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Note: *Data for 2018 and 2019 are preliminary; Based on analysis of 461 NPS; Boundaries, names and designations used do not 
imply official endorsement or acceptance by the United Nations.  
Source: UNODC Early Warning Advisory (EWA) on NPS.
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Figure 21. Proportion of NPS in East and Southeast 
Asia by pharmacological effect, up to December 2019* 
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Note: * Data for 2018 and 2019 are preliminary; Based on 
analysis of 451 synthetic NPS reported to the EWA; Plant-based 
substances were excluded from the analysis as they usually 
contain a large number of different substances some of which 
may not even be known and whose effects and interactions are 
not fully understood. Percentage sum may exceed 100% due to 
rounding of decimals. 
Source: UNODC EWA on NPS; Country reports presented 
by national authorities at the Regional SMART workshop, 
Singapore, August 2019. 
The number of NPS with opioid effects identified 
in East and Southeast Asia has increased steadily 
in recent years. While there were only three 
synthetic opioids identified in the region by 2015, 
this figure has increased to 28 substances by 2019. 
Some synthetic opioids identified in the region 
are extremely potent and have been implicated in 
overdose deaths outside the region, particularly in 
North America and to a lesser extent in Europe.105 
Figure 22. Emergence of NPS with opioid effects in East 
and Southeast Asia, 2014-2019* 
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Note: * Data for 2018 and 2019 are preliminary. 
Source: UNODC EWA on NPS. 
105 UNODC, “Understanding the global opioid crisis”, Global SMART 
Update vol 21, 2019. 
There is little information relating to overdose 
deaths associated with the non-medical use of 
synthetic opioids in East and Southeast Asia, despite 
the steady emergence of NPS with opioid effects 
in recent years. However, given the large heroin 
market in the region, there is a risk that organised 
crime groups may substitute or adulterate the 
heroin supply with synthetic opioids to potentially 
lower cost and maximise their profits, or during 
a supply shock event. This highlights the need to 
improve the forensic capacity of several countries 
in the region to enable them to identify synthetic 
opioids and respond early on should these 
substances emerge on the drug market.
There are already some indications of the availability 
of synthetic opioids in the regional drug market. 
For instance, in January 2018, Canadian authorities 
reported a seizure of fentanyl106 trafficked via an 
express cargo from Thailand, which was the first 
fentanyl seizure in connection with the country.107 
In addition, the UNODC EWA on NPS has received 
reports of the identification of a number of potent 
NPS with opioid effect, in particular fentanyl 
analogues, in East and South East Asia over the past 
couple of years.
According to retrospective forensic data of autopsy 
cases from Thailand, fentanyl or norfentanyl (a 
metabolic product of fentanyl) was detected 
in 31 cases between 2016 and 2018 in the 
country.108 Of the 31 cases, about 42 per cent 
(13 cases) were found with benzodiazepines, 
such as diazepam and clonazepam, and two of 
them showed the concurrent use of fentanyl with 
methamphetamine.109 Although it is unclear what 
proportion of cases was associated with the non-
medical use of synthetic opioids, the findings 
show the need for more research on this topic, 
considering the limited information on drug 
overdose across countries in the region. 
106 Fentanyl is not an NPS, however, the information on fentanyl 
was included in the NPS section due to the coincidence of the 
non-medical use of fentanyl and the emergence of NPS with 
opioid effects observed in other parts of the world.  
107 Official communication with the Canada Border Service Agency, 
October 2018.
108 Official communication with the Forensic Drug Addict Network 
of Thailand, April 2020; The network is composed of 29 
institutes operating in the field of forensic medicine in Thailand 
with support from Thai authorities, including the Office of 
Narcotics Control Board (ONCB). 
109 Official communication with the Forensic Drug Addict Network 
of Thailand, April 2020.
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Table 1. Synthetic opioids identified for the first time in 
East and Southeast Asia, 2018-2020
Year reported Substance name
2018 Tetrahydrofuranylfentanyl 
isopropyl-U-47700
4-Chloroisobutyrfentanyl
Benzoylfentanyl
N-Methylnorfentanyl
Benzylfuranylfentanyl
2019 Cyclopentylfentanyl
2-Fluorofentanyl
4-Methoxybutyrfentanyl
2020 Crotonylfentanyl
Source: UNODC EWA on NPS.
The non-medical use of benzodiazepine-type NPS 
in East and Southeast Asia remains a concern, with 
the region reporting a total of 11 benzodiazepine-
type substances between 2013 and 2019. It appears 
that many of these substances have been detected 
in “Erimin-5” tablets.110 For instance, Singapore 
authorities identified several benzodiazepines, 
including phenazepam, etizolam, clozapine and 
carbamazepine, in tablets sold as “Erimin-5” in 
recent years.111    
Available data, albeit limited, reported from 
countries in East and Southeast Asia indicate inter- 
as well as intra-regional NPS trafficking. Indonesia 
reported China as the main embarkation point for 
synthetic cannabinoids consumed in the country in 
2018.112 Moreover, Hong Kong authorities reported 
that several synthetic cathinones with stimulant 
effect, such as 3,4-methylenedioxypyrovalerone 
(MDPV), 4-methylmethcathinone (mephedrone), 
and methylone (bk-MDMA)113, mainly sourced from 
the mainland China, were destined for the United 
States, France, and the United Kingdom.114   
110 Erimin 5 is a proprietary product of Sumitomo corporation, 
and its licit production has been discontinued since 
2015. The proprietary product contains nimetazepam, a 
benzodiazepine, which is controlled in Schedule IV of the 
Convention on Psychotropic Substances of 1971. It is probable 
that current ‘Erimin 5’ seizures are manufactured illicitly 
and may or may not contain nimetazepam as well as a range of 
other substances.
111 Health Sciences Authority (HSA) of Singapore, “Unusual exhibits 
found in Singapore”, presented at the 2019 SMART Regional 
Workshop, Singapore, August 2019.
112 ARQ data.
113 3,4-Methylenedioxypyrovalerone (MDPV),  
4-Methylmethcathinon (mephedrone), and methylone (bk-
MDMA) were added to the list of Schedule II of the Convention 
on Psychotropic Substances of 1971 at the 2015 Commission on 
Narcotic Drugs. 
114 UNODC, responses to the annual report questionnaire.
The non-medical use and supply of ketamine 
persist in East and Southeast Asia  
While the non-medical use of ketamine has long 
been a challenge for East and Southeast Asia, there 
have been changes in the ketamine market in recent 
years. As with methamphetamine, seizures of 
ketamine have increased significantly in Southeast 
Asia since 2015. In 2019, at least four tons of the 
drug were seized, representing a 14-fold increase 
compared to the amount seized in 2014. Almost all 
ketamine seizures in 2019 was reported from one 
of four countries in the region: Malaysia, Myanmar, 
Thailand, and Viet Nam. Another notable trend 
was observed in Taiwan Province of China where 
seizures of ketamine in 2019 amounted to nearly 4.2 
tons, larger than the combined amount of ketamine 
seizures reported in the three preceding years.115 In 
contrast to the trends observed in Southeast Asia 
and Taiwan Province of China, seizures of ketamine 
in China decreased significantly in recent years. In 
2018, Chinese authorities seized 5.7 tons of the 
drug, more than an 80 per cent decrease compared 
to its peak in 2015 (19.6 tons)  
The steep surge in seizures of ketamine in 
Southeast Asia has been primarily driven by 
substantial quantities of the drug being illicitly 
manufactured in, and trafficked from, Myanmar. 
In 2019, a number of large shipments of ketamine 
packaged in distinctive teabags originating from the 
Golden Triangle were seized in several countries, 
including China, Malaysia, Thailand and Viet Nam. 
Authorities in China noted that about a quarter 
of ketamine seized in 2018 was sourced from the 
Golden Triangle.116 The steep increases in seizures 
of ketamine in Taiwan Province of China also 
appear to have been driven in part by intensified 
flows of ketamine trafficked from Southeast Asia. 
For instance, in January 2019, authorities of Taiwan 
Province of China seized about 320 kg of the drug 
trafficked from Thailand.117 
115 Ministry of Justice of Taiwan Province of China, “Annual drug 
statistics”, February 2020. 
116 NNCC, “Latest situation of synthetic drugs in China”, presented 
at the Global SMART Programme Regional Workshop, 
Singapore, August 2019.
117 Ministry of Justice Investigation Bureau, “Taiwan Province of 
China, Thailand, and the United States cooperate to jointly seize 
52 kilograms of Ketamine from international drug trafficking 
organization”, official press release, May 2019. 
28
Synthetic Drugs in East and Southeast Asia
Figure 23. Seizures of ketamine in East and Southeast 
Asia, 2014-2019*  
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Note: * Data for 2019 include only those confirmed by countries 
in the region. For more information, see footnote 13 of the 
report. 
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; Comparison of 2019 and 2018 crime situation, Hong 
Kong Police Force, (accessed at https://www.police.gov.hk/
ppp_en/09_statistics/csc_2018_2019.html).
Data on non-medical use of ketamine, albeit 
limited, paint a mixed picture in relation to trends 
in demand for illicit ketamine in East and Southeast 
Asia. For instance, the number of treatment 
admissions due to the non-medical use of ketamine 
in Thailand increased by more than 20 times over 
the last five years, from just over 50 people in 
2014 to 1,069 in 2019.118 In contrast, the number 
of registered ketamine users in China decreased 
significantly. By the first half of 2019, there were 
50,000 registered ketamine users, which is almost 
one-fifth of the number reported in 2015 (236,000 
users).119 
Sources of ketamine found in East and 
Southeast Asia have diversified 
Although most of the ketamine available in the 
regional drug market is being supplied from within 
the region, there are also indications that supply 
routes from other regions exist as well. According 
to the Hong Kong Customs and Excise Department, 
of the 307.8 kg of ketamine seized during the first 
eleven months of 2019, about one-third (99.9 kg) 
was trafficked from countries in Europe, including 
Belgium, France, Germany, the Netherlands and 
Spain.120 
118 DAINAP; Official communication with ONCB, February 2020. 
119 NNCC, “Ketamine abuse and illicit manufacture”, presented 
at the Global SMART Programme Regional Workshop, Beijing, 
China, August 2015; NNCC, “Update on Efforts to Achieve 
Mekong MOU SAP X Thematic Areas Outputs at the National 
Level”, presented at the 2019 Mekong MOU SOC Meeting, 
Bangkok, Thailand, November 2019. 
120 The Hong Kong Customs and Excise Department, “Seizures of 
ketamine by Hong Kong Customs”, shared with UNODC through 
the official communication in January 2020.  
Figure 24. Seizures of ketamine by the Hong Kong 
Customs and Excise Department, 2017-2019*  
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Note: * Data for 2019 cover the first eleven months of the year. 
Source: Official communication with the Hong Kong Customs 
and Excise Department, January 2020. 
Ketamine manufactured at clandestine laboratories 
in South Asia is another source for the East and 
Southeast Asia market. For instance in May 2019, 
Indian authorities dismantled a clandestine 
ketamine laboratory in Bengaluru and arrested 
members of a syndicate involved in trafficking 
ketamine to Malaysia.121 In addition, in March 2019, 
Malaysian authorities seized 322 kg of ketamine 
trafficked from Pakistan. 122   
121 Narcotics Control Bureau (NCB), India, “Country briefing on drug 
and precursor situation in India”, presented at the Meeting of 
Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, 
February 2020.  
122 Royal Malaysian Police, National Anti-Drug Agency (NADA), and 
the Ministry of Health of Malaysia, “Country briefing” presented 
at Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020. 
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Brunei Darussalam
Methamphetamine 
• Crystalline methamphetamine continues to account for the largest proportion of the total number of 
drug related offences and treatment admissions in recent years (see Figure 1 and Table 2).
• The amount of crystalline methamphetamine seized annually has increased significantly in 2019, with 
annual seizures in 2019 almost double the combined annual seizures in the last four years (see Table 
3).
“Ecstasy”1  
•	 The use of “ecstasy”, as evidenced by data for seizures and arrests, remains low (see Figure 1 and 
Table 3).
New psychoactive substances (NPS)
•	 While the non-medical use of ketamine and other NPS was not reported in 2019, seizures and price 
data suggest that it might exist (see tables 3 and 4). 
•	 In 2019, national authorities seized bottles suspected to contain a synthetic cannabinoid.2 The country 
also made its first seizures of khat, which originated from Ethiopia, and also of kratom (see Table 3).3
Other drugs 
•	  ‘Erimin 5’ continues to be marketed and used in the country.4 
1  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of 
MDMA.   
2  Drug Abuse Information Network for Asia and the Pacific (DAINAP); National authorities have not provided a name of the suspected 
synthetic cannabinoid at the time of writing. 
3  Ibid; Official communication with the Narcotics Control Bureau (NCB), Brunei Darussalam, February 2020.
4  Erimin 5 is a proprietary product of Sumitomo corporation, and its licit production has been discontinued since 2015. The proprietary 
product contains nimetazepam, a benzodiazepine, which is controlled in Schedule IV of the Convention on Psychotropic Substances of 1971. 
It is probable that current ‘Erimin 5’ seizures are manufactured illicitly and may or may not contain nimetazepam as well as a range of other 
substances.
CAMBODIA
Summary of major trends and emerging concerns
BRUNEI DARUSSALAM
32
Synthetic Drugs in East and Southeast Asia
Key facts and figures  
Drug demand indicators 
Table 1. Trend in use of selected drugs in Brunei Darussalam, 2014-2019*
Drug type 2014 2015 2016 2017 2018 2019
Crystalline methamphetamine      
“Ecstasy”      
Cannabis herb      
Inhalants    ●  
Ketamine      ●
Nimetazepam ●     
Note: * Based on expert perception provided by NCB, Brunei Darussalam.  
 = Increase,  = Decrease,   = Stable, ● = Not reported 
Source: UNODC, responses to the annual report questionnaire; DAINAP; Official communication with NCB, February 2020. 
Figure 1. Number of people brought into formal contact with authorities for drug-related offences in Brunei 
Darussalam by drug type, 2014-2019 
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Source: DAINAP; NCB, “Synthetic drug situation in Brunei Darussalam”, presented at the 2019 SMART Regional Workshop, 
Singapore, August 2019; Official communication with NCB, February 2020. 
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Table 2. Number of people who use drugs receiving treatment by gender and selected drug types, 2017-2019   
2017 2018 2019
Drug type Male Female Total Male Female Total Male Female Total
Methamphetamine 190 30 220 218 32 250 195 31 226
Cannabis 2 0 2 3 0 3 4 0 4
Inhalants 2 0 2 0 0 0 1 0 1
Polydrug use 1 0 1 2 0 2 1 0 1
Total 195 30 225 223 32 255 201 31 232
Source: DAINAP; NCB, “Synthetic drug situation in Brunei Darussalam”, presented at the 2019 SMART Regional Workshop, 
Singapore, August 2019.
Drug supply indicators  
Table 3. Seizures of selected drugs in Brunei Darussalam, 2014-2019 
Drug type Unit 2014 2015 2016 2017 2018 2019 
Crystalline 
methamphetamine kg 4.3 1.4 0.7 0.8 0.8 6.4
“Ecstasy” tablet /g 25 tablets and 0.5 g
42 tablets 
and 30.4 g 21 tablets 
31 tablets 
and 1.6 g 0 42 tablets 
Cannabis herb kg 8.7 3.8 6 1.1 0.4 1.4
Heroin kg 8.1 ● ● ● ● ●
Ketamine tablet /g
14 tablets 
and 
123.1 g
10.2 g 17.6 g
50 tablets 
and 
54.5 g
21 g 1.6 g
Nimetazepam tablet/g 570 tablets 243 tablets and 4.1 g
457 tablets 
and 1.4 g
453 tablets 
and 11.8 275 tablets 
503 tablets 
and 0.3 g
Kratom (liquid) litre 0 0 0 0 0 9
Khat kg 0 0 0 0 0 80
Note: ●= Not reported. 
Source: UNODC, responses to the annual report questionnaire; DAINAP; NCB, “Synthetic drug situation in Brunei Darussalam”, 
presented at the 2019 SMART Regional Workshop, Singapore, August 2019; Official communication with NCB, February 2020. 
Table 4. Retail prices of selected illicit drugs in Brunei 
Darussalam in BN$ (US$), 2019 
Drug type Unit 2019
Crystalline 
methamphetamine per g
195
(144)
“Ecstasy” per tablet 30-50
(22-37)
Cannabis herb per g 15(11)
Ketamine per g 50 
(37)
Benzodiazepines (Erimin 5) per tablet 10
(7)
Note: NCB reported the same retail prices for the selected 
illicit drugs in BN$ for 2017 and 2018; The conversion ratio 
used is 1 BN$ = 0.74 US$ (as of 03 February 2020).  
Source: DAINAP; Official communication with NCB, February 
2020. 
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Cambodia
Methamphetamine 
•	 The market for crystalline methamphetamine continues to expand, with seizures in 2019 (385 kg) 
being the largest amount on record (see Table 3).
•	 The number of drug users brought into formal contact with authorities in Cambodia in 2019 has almost 
doubled since 2014 (see Figure 1) with users of crystalline methamphetamine forming the largest 
proportion of users in drug treatment centers in 2018 (latest year available, see Table 2). 
•	 Notwithstanding the significant annual seizures of methamphetamine in tablet and crystalline forms, 
average retail prices have dropped to their lowest level on record, indicating widespread availability 
(see Figures 3 and 4).
“Ecstasy”1 
•	 The amount of “ecstasy” tablets seized annually has seen significant increases in recent years (see 
Table 3), alongside a noticeable increase in its typical MDMA content (see Table 4).
•	 In December 2019, national authorities dismantled a clandestine laboratory for tableting “ecstasy” in 
Phnom Penh, resulting in seizures of 74.8 kg of MDMA in crystalline and liquid form.2 
New Psychoactive Substances (NPS)
•	 The annual amounts of ketamine seized in 2018 and 2019 were a multiple of the amounts seized in 
previous years (see Table 3) and the non-medical use of ketamine seems to be on the increase in the 
country (see Table 1). 
•	 There is no reported use of other NPS in the country. 
Other drugs 
•	 In April 2019, Cambodian authorities dismantled a clandestine laboratory producing pyrovalerone 
tablets. Follow-up investigations revealed that the drug was meant to be sold as “ecstasy” in the 
country.3
1  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of 
MDMA.  
2  National Authority for Combating Drugs (NACD), “Country briefing”, presented at the Meeting of Drug Forensic Specialists, Beijing, China, 
December 2019. 
3  NACD, “Country briefing”, presented at the Meeting of Drug Forensic Specialists, Beijing, China, December 2019; Bilateral meeting between 
NACD and UNODC, February 2020. Pyrovalerone is a substance listed under Schedule IV of the Convention on Psychotropic Substances of 
1971.
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Key facts and figures  
Drug demand indicators  
Table 1. Trends in use of selected drugs in Cambodia, 2014-2019*
Drug type 2014 2015 2016 2017 2018 2019
Methamphetamine tablets      
Crystalline methamphetamine      
Ecstasy ●     
Cannabis herb ●     
Cocaine ●    ● 
Heroin ●     
Ketamine ●  ●  ● 
Note: * Based on expert perception provided by NACD, Cambodia.
 = Increase,  = Decrease,   = Stable, ● = Not reported. 
Source: Drug Abuse Information Network for Asia and the Pacific (DAINAP).
Figure 1. Number of people who use drugs brought into formal contact with authorities in Cambodia, 2014–2019
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Source(s): DAINAP; NACD, “Synthetic drug situation in Cambodia”, presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019; NACD, “Report on achievements during January-September 2019”, December 2019; Official communication with 
NACD, March 2020. 
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Table 2. Number of treatment admissions in Cambodia by drug type and gender, 2018*
Drug type Male Female Total
Crystalline methamphetamine 3,540 147 3,687
Methamphetamine tablet 462 9 471
“Ecstasy” 163 0 163
Heroin 21 4 25
Ketamine 25 1 26
Cannabis herb 17 0 17
Other drugs 148 6 154
Total 4,376 167 4,543
Note: * Data in the table only cover drug users admitted to temporary treatment centres; The total number of admissions for 
temporary drug treatment centres in 2018 was 4,746 and included those admitted for poly-drug use.     
Source: DAINAP; NACD, “Synthetic drug situation in Cambodia”, presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019.
Figure 2. Drug treatment centre admissions in Cambodia by age group, 2017 and 2018
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Note: * Data in the graph only cover drug users admitted to temporary treatment centres.
Source: DAINAP; NACD, “Synthetic drug situation in Cambodia”, presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019.
Drug supply indicators  
Table 3. Seizures of selected drugs in Cambodia, 2014-2019
Drug type Unit 2014 2015 2016 2017 2018 2019
Methamphetamine 
tabletsa tablets 87,000 265,760 490,689 371,556 77,000 483,402
Crystalline 
methamphetamine kg 29 72.9 66.3 80.1 306.6 384.9
“Ecstasy”b tablets 10,533 70 5,509 83,533 599,200 382,728
Cannabis herb kg 19.9 1,511.5 37 116.3 74.0 102.8
Cocaine kg 7.9 5.3 14 12.8 5.4 61.1
Heroin kg 1.8 2.5 6.2 22.5 1.3 47.9
Ketamine kg 0.0 c 0.1 1.1 6.3 36.3 33.1
Note: a These figures include quantities reported as grams; all of which were converted into estimated tablet equivalent at 90 mg 
per tablet. b These figures include quantities reported as grams; all of which were converted into estimated tablet equivalent of 300 
mg per tablet. c Less than 0.05 kg of ketamine was seized.  
Source(s): UNODC, responses to the annual report questionnaire; DAINAP; NACD, “Synthetic drug situation in Cambodia”, 
presented at the 2019 SMART Regional Workshop, Singapore, August 2019 and previous years; Official communication with NACD, 
March 2020. 
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Table 4. Typical purities of selected drugs in Cambodia, 2018-2019
2018 2019
Number 
of samples 
analysed
Minimum Average Maximum Number 
of samples 
analysed
Minimum Average Maximum 
Crystalline 
methamphetamine 4,097 1.5 52.2 80.5 5,237 2.3 58.5 96.9
Methamphetamine 
tablets 154 12.7 14.6 21.2 203 10.8 19.1 29.9
“Ecstasy” tablets 
(MDMA) 88 14.6 26.4 43.5 203 27.4 37.6 54.7
Ketamine (powder) 55 25.9 46.2 70.2 181 0.7 38.9 88.8
Heroin 4 62.6 77.2 79.7 4 44.1 71.5 90.2
Cocaine 11 65.3 73.7 80.4 3 ● ● 88.7
Note:  ● = Not reported. Data in this table refer to the weight/weight (w/w) % expressed as the hydrochloride salt of these 
substances.
Source: Official communication with NACD, March 2020. 
Figure 3. Retail prices of methamphetamine tablets in 
Cambodia in US$, 2014-2019*
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Note: *The high-low bars represent the upper and lower limits 
of the price ranges reported in addition to the typical price. 
Source: NACD, “Synthetic drug situation in Cambodia”, 
presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019; Official communication with NACD, March 2020. 
Figure 4. Retail prices of crystalline methamphetamine 
in Cambodia, 2014–2018*  
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Note: *The high-low bars represent the upper and lower limits 
of the price ranges reported in addition to the typical price. 
Source: NACD, “Synthetic drug situation in Cambodia”, 
presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019. 
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Methamphetamine 
•	 Data on drug use, together with supply indicators such as arrests, manufacture and seizures, 
indicate a possible decrease in the illicit synthetic drug market in China. The amount of crystalline 
methamphetamine seized in 2018 – the latest year available – for example, was the lowest reported 
since 2014 (see Table 1). 
•	 While the number of registered drug users of synthetic drugs has been decreasing in recent years (see 
Figure 1), methamphetamine continues to account for the nearly 60 per cent of the total number of 
registered drug users in China (see Figure 2). 
•	 In an apparent shift, increasing quantities of crystalline methamphetamine have been trafficked from 
the Golden Triangle to China. For instance, seizures of crystalline methamphetamine trafficked from 
the Golden Triangle have more than quadrupled from 1.1 tons to 4.6 tons between 2017 and 2018.1 
•	 China remains vulnerable to the risk of diversion of precursor chemicals used in the illicit manufacture 
of methamphetamine. Transnational organized crime groups in China continue to circumvent existing 
domestic and international legal frameworks using non-scheduled precursor chemicals.2 
“Ecstasy”3
•	 The amount of “ecstasy” tablets seized in 2018 was the lowest ever reported from the country since 
2015 (see Table 1).
New Psychoactive Substances (NPS) 
•	 Seizures of ketamine in China continue to decrease. The amount of ketamine seized in 2018 was less 
than one-third of the record quantity reported in 2015 (see Table 1). 
•	 Despite national measures to restrict NPS, new substances including potent synthetic opioids continue 
to emerge in the country. Between June 2018 and June 2019, synthetic cannabinoids accounted for 
the largest proportion of the total number of NPS samples detected by the country’s NPS Monitoring 
Programme, followed by synthetic cathinones (see Figure 5). 
Other drugs 
•	 The number of registered users of opiates has decreased every year since 2014 (see Figure 1). However, 
national authorities noted increased concomitant use of opiates and synthetic drugs in recent years.4 
•	 A mixture of various substances, such as methamphetamine, ketamine and MDMA, packaged in a 
bottle and sold as ‘happy water’ is a growing concern in China, as composition and concentration of 
the drugs differ from bottle to bottle, posing a risk of overdose for users.5 
   
1 	National	Narcotics	Control	Commission	(NNCC)	of	China,	“Latest	situation	of	synthetic	drugs	in	China”,	presented	at	the	2019	SMART	
Regional	Workshop,	Singapore,	August	2019.
2 	For	instance,	methyl	alpha-phenylacetoacetate	(MAPA)	has	been	increasingly	used	as	a	substitute	for	alpha-phenylacetoacetonitrile	(APAAN),	
a	substance	scheduled	in	Table	I	of	1988	UN	Drug	Convention	since	2014.	
3 	“Ecstasy”	tablets	sold	in	the	country	may	contain	a	range	of	substances	in	varying	composition	and	quantities	in	addition	or	instead	of	
MDMA.   
4 	NNCC,	“Latest	situation	of	synthetic	drugs	in	China”,	presented	at	the	2019	SMART	Regional	Workshop,	Singapore,	August	2019.
5 	Ibid.
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 Key facts and figures  
Drug demand indicators  
Figure 1. Number of people who were registered for 
using synthetic drugs and opiates in China, 2014 – 
2019*
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Note: * Data cover the first half of the year. 
Source:	NNCC,	 “Latest	 situation	of	 synthetic	drugs	 in	China”,	
presented	at	the	2019	SMART	Regional	Workshop,	Singapore,	
August 2019 and previous country briefings presented at past 
workshops.  
Figure 2. Proportion of registered drug users by type of 
drug used in China, 2019*
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Note: * Data cover the first half of the year. 
Source:	NNCC,	“Update	on	Efforts	to	Achieve	Mekong	MOU	SAP	
X	 Thematic	 Areas	Outputs	 at	 the	National	 Level”,	 presented	
at the Mekong MOU Senior Officials Committee, Bangkok, 
Thailand, November 2019.  
Drug supply indicators  
Table 1. Seizures of selected drugs in China, 2013-2018
Drug type Unit 2014 2015 2016 2017 2018
Crystalline 
methamphetamine kg 13,754.2 22,663.8 17,361.8 17,033.6 10,654.8
Methamphetamine 
tablets a tablets 126,278,556 134,126,000 129,123,556 122,410,444 138,888,888
Methamphetamine 
powder kg 282.2 393.9 399.7 332.4 354.4
Methamphetamine 
liquid lt 455.4 1,443.7 1,323.8 2,195.9 921.3
“Ecstasy” b tablets 165,333 632,100 1,200,267 3,481,233 213,600
Ketamine kg 11,212.9 19,600 10,361.1 7,292.6 5,742.9
Cannabis herb kg 3,398.6 8,721.8 5,833.3 4,919.1 6,059.8
Cannabis resin kg 0.2 5.9 34.4 8.0 0.3
Cocaine kg 114.4 97.7 430.6 311.7 1,365.8
Heroin kg 9,302.4 8,796.1 8,777.4 9,519.9 8,070.3
Opium kg 1,728.0 2,451.9 3,104.3 3,909.3 2,515.9
Note: Some of figures reported in previous reports have been updated with revised data shared by NNCC in March 2020; a Figures 
reported other than the number of tablets converted into estimated tablet equivalents at 90 mg per tablet. b Figures reported other 
than the number of tablets converted into estimated tablet equivalents at 300 mg per tablet.
Source:	UNODC,	responses	to	the	annual	report	questionnaire;	DAINAP;	NNCC,	“Annual	Report	on	Drug	Control	in	China	2019”	and	
previous reports; Official communication with NNCC March 2020. 
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Figure 3. Number of drug-related arrests in China, 
2014-2018 
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Source:	NNCC,	“Annual	Report	on	Drug	Control	in	China	2019”	
and previous reports.  
Figure 4. Number of illicit drug manufacturing facilities 
dismantled in China, 2014-2018
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Source:	NNCC,	“Annual	Report	on	Drug	Control	in	China	2019”	
and previous reports.  
Figure 5. Types of NPS identified by the NPS Monitoring 
Programme of China, June 2018 - June 2019 
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Synthe�c cannabinoids Synthe�c cathinones Others Tryptamines  
Source:	NNCC,	 “Latest	 situation	of	 synthetic	drugs	 in	China”,	
presented	 at	 the	 Global	 SMART	 Programme	 Regional	
Workshop, Singapore, August 2019.
Figure 6. Top 10 synthetic cannabinoids identified by 
the NPS Monitoring Programme of China, June 2018-
June 2019
0 20 40 60 80 100 120 140 160
4F-MDMB-BUTINACA
CUMYL-5F-PICA
Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate
5CI-AB-PINACA
5F-MMB-PICA
MMB-CHMICA
5CI-AKB48
5F-MDMB-PINACA
MMB-FUBINACA
5-F-MDMB PICA
Number
Source:	NNCC,	 “Latest	 situation	of	 synthetic	drugs	 in	China”,	
presented	at	the	2019	SMART	Regional	Workshop,	Singapore,	
August 2019.
Figure 7. Top 10 synthetic cathinones identified by the 
NPS Monitoring Programme of China, June 2018-June 
2019
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Source:	NNCC,	 “Latest	 situation	of	 synthetic	drugs	 in	China”,	
presented	at	the	2019	SMART	Regional	Workshop,	Singapore,	
August 2019.
Table 2. Typical retail purities (per cent) of 
methamphetamine and ketamine in China, 2016 – 2018
Drug type 2016 2017 2018
Crystalline 
methamphetamine 
94 94 89
Methamphetamine 
tablet
15 15.5 15.6
Ketamine 90 87 95
Note: Data in this table refer to the weight/weight (w/w) % 
expressed as the hydrochloride salt of these substances.
Source:	NNCC,	 “Latest	 situation	of	 synthetic	drugs	 in	China”,	
presented	 at	 the	 Global	 SMART	 Programme	 Regional	
Workshop, Singapore, August 2019.
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Hong Kong (Special Administrative Region of China)
Summary of major trends and emerging concerns
Methamphetamine 
•	 The number of reported users of crystalline methamphetamine in Hong Kong, China, has decreased 
significantly in recent years (see Figure 1). While there is no clear trend in seizures of the drug, an 
increase in the retail price has been reported (see Tables 1 and 2).
•	 Preliminary data for 2019 show the proportion of female methamphetamine users brought into formal 
contact with authorities was higher than for any other drug (see Figure 2).   
Ecstasy6 
•	 Record	amounts	of	“ecstasy”	were	seized	in	Hong	Kong,	China,	in	2019,	but	the	number	of	“ecstasy”	
users accounted for only 0.5 per cent of the total reported drug users in 2018.7 
New Psychoactive Substances (NPS)  
•	 The number of reported persons with non-medical use of ketamine has declined strongly in Hong 
Kong, China, in recent years (see Figure 1). However, the typical retail price and amount of ketamine 
seized annually have generally increased since 2016 (see Tables 1 and 2). The Hong Kong Customs and 
Excise	Department	has	also	reported	increasing	quantities	of	the	drug	being	trafficked	from	Europe	
since 2019.8
•	 Hong Kong, China, remains a major transit point for NPS, specifically synthetic cathinones being 
trafficked from China en route	to	other	regions,	including	Europe	and	North	America.	In	2018,	a	total	of	
187kg	of	synthetic	cathinones	were	seized	by	the	Hong	Kong	Customs	and	Excise	Department,	making	
it the second largest seizure by quantity after cocaine.9 
Other drugs 
•	 Although there has been a downward trend in the number of heroin users since 2014 (see Figure 1), 
the drug remains the most commonly reported substance of abuse in Hong Kong, China.   
•	 The use of cocaine has been on the rise in Hong Kong, China, evidenced by increases in the number of 
reported cocaine users and annual seizures (see Figure 1 and Table 1). 
  
 
6 	“Ecstasy”	tablets	sold	in	the	country	may	contain	a	range	of	substances	in	varying	composition	and	quantities	in	addition	or	instead	of	
MDMA.   
7 	Narcotics	Division,	Security	Bureau	(NDSB),	“Newly/previously	reported	drug	abusers	by	age	group	by	common	type	of	drugs	abused	(T3)”	
(accessed at http://www.nd.gov.hk/text/en/stat/statistics_list.htm).
8 	Ibid. 
9 	The	Hong	Kong	Customs	and	Excise	Department,	“Drug	Trafficking	Trend	in	Hong	Kong,	presented	at	the	Pre-Operational	Meeting	of	
Operation	ICE	Break”,	Seoul,	the	Republic	of	Korea,	October	2019.		
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Key facts and figures  
Drug demand indicators  
Figure 1. The number of reported users of methamphetamine, ketamine, heroin, and cocaine in Hong Kong, China, 
2014 – 2019*
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Note: * Data cover the first nine months of the year. 
Source:	NDSB,	Hong	Kong,	China,	“Newly/previously	reported	drug	abusers	by	age	group	by	common	type	of	drugs	abused	(T3)”	
(accessed at http://www.nd.gov.hk/text/en/stat/statistics_list.htm). 
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Figure 2. The number of people who use methamphetamine, ketamine, heroin, and cocaine in Hong Kong, China, 
by sex, 2019*
Note: * Data cover the first nine months of the year. 
Source:	Narcotics	Division,	Security	Bureau	(NDSB),	“Newly/previously	reported	drug	abusers	by	age	group	by	common	type	of	
drugs abused (T3)” (accessed at http://www.nd.gov.hk/text/en/stat/statistics_list.htm). 
Drug supply indicators  
Table 1. Seizures of selected drugs in Hong Kong, China, 2014-2019*
Drug type Unit 2014 2015 2016 2017 2018 2019*
Crystalline 
methamphetamine kg 1,027.5 355.5 359.0 144 164.1 410
“Ecstasy”a tablets 2,167 2,833 6,400 98,467 104,633 1,127,709
Ketamine kg 509.3 499.4 281.7 94.5 152.7 388
Cannabis kg 37.9 52.9 181.6 661.4 226.6 402
Cocaine kg 272.0 226.9 433.5 454 827.5 1,317
Heroin kg 88.9 27.4 73.5 29.5 43.9 62
Note: * Data for 2019 were reported by the Hong Kong Police Force and are preliminary. Some of the figures reported in previous 
reports have been updated with revised data shared by the Hong Kong Customs and Excise Department in March 2020; a Figures 
reported other than in number of tablets were converted into estimated tablet equivalents at 300 mg per tablet. 
Source:	UNODC,	responses	to	the	annual	report	questionnaire;	Official	communication	with	the	Hong	Kong	Customs	and	Excise	
Department, March 2020; Comparison of 2019 and 2018 crime situation, Hong Kong Police Force, “Comparison of 2019 and 2018 
Crime	Situation”,	(accessed	at	https://www.police.gov.hk/ppp_en/09_statistics/csc_2018_2019.html).	
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Table 2. Wholesale and retail prices of selected drugs in Hong Kong, China, in US$, 2016 – 2018
Drug type Unit 2016 2017 2018
Crystalline methamphetamine Per kg 8,180 11,820 22,325.3(17,886-26,347)
Crystalline methamphetamine per gram 42 45.6 70(57.3-89.2)
“Ecstasy”	 per tablet 7.7 10.2 10.2(9.6-10.7)
Heroin per gram 96 90.1 – 109 108.3(90.2-126.6)
Ketamine per gram 28.2 48.7 65.4(51.9-77.8)
Cocaine per gram 141 148.4 – 178.5 ●
Note: ● = Not reported. 
Source:	UNODC,	 responses	 to	 the	 annual	 report	 questionnaire;	Hong	 Kong	 Police	 Force,	 “Narcotics	 Bureau	 Territory	 Report”,	
shared	at	the	2018	ADLOMICO	meeting,	Busan,	the	Republic	of	Korea,	September	2018.		
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Indonesia
Methamphetamine 
•	 The amounts of crystalline methamphetamine seized annually have increased significantly in recent 
years, with the record amount of seizures in 2019 (17.9 tons) exceeding the combined amounts 
recorded for two previous years (see Table 3).
•	 Despite substantial seizures, the typical price for 1 gram of crystalline methamphetamine has nearly 
halved over the last four years to US$ 85.7-114.3 in 2019 (see Table 5), while demand is assessed as 
stable and products of a consistently high  purity  (see Tables 1 and 4), indicating a high availability. 
•	 Methamphetamine also accounts for the largest proportion of drug-related arrests (see Figure 2) and 
persons placed in drug treatment in the country (see Table 2) in recent years.
 
“Ecstasy”1
•	 Indonesia continues to account for the largest amount of “ecstasy” seized in Southeast Asia.2
•	 Although the drug appears to have been largely supplied from overseas, Indonesian authorities have 
dismantled clandestine “ecstasy” laboratories in recent years (see Figure 3). 
New Psychoactive Substances (NPS)
•	 Synthetic cannabinoids dominate the NPS market in Indonesia, a trend observed since 2017 (see 
Figure 4). According to the latest drug use survey among workers conducted in 2018, a synthetic 
cannabinoid product known as ‘Gorilla Tobacco’ is the fifth most widely used drug, after cannabis, 
methamphetamine, analgesics, and “ecstasy”.3   
Other drugs 
•	 Demand for clandestinely manufactured tablets containing paracetamol, carisoprodol, and caffeine, 
sold as “PCC”4, appears to have increased in recent years. In November 2019, Indonesian authorities 
dismantled a clandestine PCC tableting facility resulting in seizures of 1.8 million PCC tablets, as well 
as its precursor chemicals.5 
•	 Annual seizures of barbiturates have remained at elevated levels with a concomitant increase in 
demand in recent years (see Table 3).
   
 
1  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of 
MDMA.   
2  For more information, see the Regional Overview of the report. 
3  National Narcotics Board (BNN), “Latest situation on synthetic drugs and responses to the threats in Indonesia”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019.
4  Carisoprodol is a centrally acting muscle relaxant, available as a prescription drug since 1959. Due to its abuse potential, Indonesia has 
revoked the distribution of pharmaceutical products containing carisoprodol in 2013 and listed carisoprodol as a Class I Narcotic in 2018.
5  BNN, “Precursor chemical situation in Indonesia”, presented at the Meeting of Drug Forensic Specialists, Beijing, China, December 2019.
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Key facts and figures  
Drug demand indicators  
Table 1. Trends in use of selected drugs in Indonesia, 2014-2018*
Drug type 2014 2015 2016 2017 2018
Crystalline methamphetamine     
“Ecstasy”     
Barbiturates     
Benzodiazepines     
Cannabis herb     
Cannabis resin    ● ●
Cocaine  ●   
Heroin     
LSD ● ●   
Ketamine   ● ● ●
Note: * Based on expert perception provided by the BNN, Indonesia. 
 = Increasing,  = Decreasing,   = Stable, ● = Not reported
Source: UNODC, responses to the annual report questionnaire; Drug Abuse Information Network for Asia and the Pacific (DAINAP). 
Table 2. Drug treatment admissions by drug type and gender in Indonesia, 2018
Drug type
All admissions
Male Female Total 
Methamphetamine* 5,439 599 6,038
Opiates** 529 47 576
Cannabis 1,764 55 1,819
Cocaine 28 3 31
Benzodiazepines 782 104 886
Barbiturates 115 8 123
LSD 473 87 560
Inhalants 441 37 478
Poly-drug use 274 0 274
Other drugs 25 0 25
Total 9,870 940 10,810
Note: * Includes few “ecstasy” related admissions. ** Include heroin, morphine and methadone. 
Source: BNN; “Latest situation on synthetic drugs and responses to the threats in Indonesia”, presented at the 2019 SMART 
Regional Workshop, Singapore, August 2019.
Drug supply indicators  
Table 3. Seizures of selected drugs in Indonesia, 2014-2019*
Drug type Unit 2014 2015 2016 2017 2018 2019*
Crystalline 
methamphetamine kg 1,125.1 4,420.2 2,630 7,544.8 8,231.3 17,900
Methamphetamine 
powder kg ● ● ● ● 4 26
Amphetamine kg ● 1.1 ● 0.0 a 65.4 239.2
“Ecstasy” tablets 489,311 1,995,240 1,694,970 3,102,679 1,594,084 1,635,852
“Ecstasy” powder kg ● 4.3 0.9 21.1 2.3 41.8
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Barbiturates tablets 9,571 7,332 273,201 264,107 138,516 226,711
Benzodiazepines tablets 356,631 1,247,895 475,860 64,962 10,703 9,472
Cannabis herb kg 68,542 29,389.3 15,700 151,670.9 41,266.75 7,675.5
Cannabis plants plants 92,481 101,815 2,171,841 205,708 1,047,915 4,520
Cocaine kg 0.4 0.0a 0.4 0.1 8.39 2
Heroin kg 12.2 13.3 2.2 0.5 1.4 16.4
Prescription opioid 
(tramadol) tablets ● ● ● ● 7,477 3,476
Ketamine kg 13.4 3.5 0 1.8 22.2 5.1
Synthetic cannabinoids kg ● ● 10.5 45.2 5.4 12.1
PCC (paracetamol, 
carisoprodol, and 
caffeine)
tablet ● ● ● ● 1,652,864 3,967
Note: * Data cover the first nine months of the year, excluding crystalline methamphetamine and “ecstasy” which cover the whole 
year of 2019 (preliminary). ● = Not reported. a Less than 0.05 kg of the substance was seized.  
Source: UNODC, responses to the annual report questionnaire; DAINAP; BNN; “Latest situation on synthetic drugs and responses 
to the threats in Indonesia”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019; Official communication 
with BNN, April 2020. 
Figure 1. Number of drug-related arrests by drug type, 2014-2019*
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Note: * Data cover the first nine months of the year. Other drugs include other psychotropic drugs and dangerous substances.
Source: DAINAP; BNN, “Latest situation on synthetic drugs and responses to the threats in Indonesia”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019. 
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Figure 2. Proportions of drug-related arrests in Indonesia by drug type, 2018 and 2019* 
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Note: * Data cover the first nine months of the year. Other drugs include other psychotropic drugs and dangerous substances.
Source: DAINAP; BNN, “Latest situation on synthetic drugs and responses to the threats in Indonesia”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019. 
Figure 3. Number of illicit ATS manufacturing facilities 
dismantled in Indonesia, 2014-2019
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Source: DAINAP; Official communication with BNN, April 2020. 
Table 4. Typical purities of crystalline 
methamphetamine in Indonesia, 2017-2018 
Year Number of samples analysed Purity (%)* 
2017 8 67.05(61.66-97.55)
2018 38 91.92(75.33-95.48)
Note: *Data in this table refer to the weight/weight (w/w) % 
expressed as the hydrochloride salt of methamphetamine.
Source: BNN, “Latest situation on synthetic drugs and 
responses to the threats in Indonesia”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019.
Table 5. Typical retail prices (US$) of selected drugs in Indonesia, 2016-2019*
Drug type Unit 2016 2017 2018 2019*
Crystalline methamphetamine per g 185 -190 153 – 185 124-185 85.7-114.3
“Ecstasy” per tablet 18 18 -31 18-28 24.3-28.6
Amphetamine per g 30 30 30 ●
Ketamine per g ● 77 ● 50-71.4
Cannabis herb per kg 185 – 191 185 – 191 185 ●
LSD Per stamp ● ● ● 10.7-21.4
Synthetic cannabinoids 
Per bag (5 
grams) ● ● ● 28.6-35.7
Heroin per g 111 - 115 111 - 115 185 214.3
Cocaine per g 74 74 74-241 179
Note: * Data cover the first nine months of the year. ● = Not reported. Indonesia reported prices with a conversion ratio of 1 USD = 
IDR 13,500 – 14,500 during the reporting period.   
Source: UNODC, responses to the annual report questionnaire; DAINAP.
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Figure 4. Number of NPS samples identified and analysed in Indonesia by substance group, 2013-2018
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Source: BNN, “Latest situation on synthetic drugs and responses to the threats in Indonesia”, presented at the 2019 SMART 
Regional Workshop, Singapore, August 2019.
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Japan
Methamphetamine  
•	 In 2019, a record high of 2.3 tons of crystalline methamphetamine was seized in Japan (see Table 
2). This increase was driven primarily by large maritime interdictions of approximately 1 ton of 
methamphetamine in June and another 600 kg of the drug in December 2019.1  
•	 Several countries in Southeast Asia, especially Thailand and Malaysia are perceived as primary 
embarkation points in terms of number of cases involving methamphetamine seized in Japan in 2018. 
(see Figure 6). 
•	 The typical price of crystalline methamphetamine in Japan remains the highest in East and Southeast 
Asia, making the country an attractive target for local and transnational organized crime groups (see 
Figure 5 in the regional chapter). 
“Ecstasy”2
•	 While the number of people brought into formal contact with authorities for “ecstasy” remains low in 
Japan (2018: 57 people), seizures of the drug have increased six-fold between 2018 and 2019 to more 
than 74,000 tablets (see Table 2).  
New Psychoactive Substances (NPS)
•	 Although the smuggling and use of NPS remains a concern for Japan, the number of people brought 
into formal contact with authorities for NPS has been rapidly decreasing in recent years (see Figure 9), 
in parallel with the introduction of national legislative controls on NPS. 
•	 Synthetic cannabinoids continue to account for the largest proportion of the total number of NPS 
reported from the country (see Figure 10). The Government of Japan scheduled several synthetic 
cannabinoids in 2019, including ADB-CHMICA and MAB-CHMICA.3 
Other drugs 
•	 Both the number of people brought into formal contact with authorities for cannabis and the amount 
of cannabis herb seized annually have been rising rapidly in Japan in recent years. (see Table 2 and 
Figure 5). 
•	 The latest drug use survey amongst high school students in Japan indicates that lifetime and past-
year use of cannabis is more prevalent than the use of other substances such as methamphetamine, 
cocaine, NPS and MDMA (see Figure 1)
•	 There are indications of Japan being increasingly targeted by organized crime groups for cocaine 
trafficking.4 
   
  
1  Ministry of Health, Labour and Welfare (MHLW) of Japan, “Latest situation on synthetic drugs and responses to the threats in Japan”, 
presented at the SMART Regional Workshop, Singapore, August 2019; National Police Agency (NPA) of Japan, “Drug Control in Japan”, 
presented at the 25th Asia-Pacific Operational Drug Enforcement Conference, Tokyo, Japan, February 2020.  
2  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of 
MDMA.   
3  MHLW of Japan, “Latest situation on synthetic drugs and responses to the threats in Japan”, presented at the SMART Regional Workshop, 
Singapore, August 2019.
4  For instance, Japanese authorities reported to have seized 177 kg and 400 kg of cocaine respectively in August and October 2019; NPA, 
“Drug Control in Japan”, presented at the 25th Asia-Pacific Operational Drug Enforcement Conference, Tokyo, Japan, February 2020.   
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Key facts and figures  
Drug demand indicators  
Table 1. Trends in use of selected drugs in Japan, 2009-2017
Drug type 2009 2011 2013 2015 2017
Crystalline methamphetamine $ # ↑ 1 1
Ecstasy 1 $ ↑ $ #
Cannabis # $ ↓ ↓ #
NPS ● ● ● $ $
Note: # = Increase, $ = Decrease, 1  = Stable, ● = Not reported. 
Source: UNODC, responses to the annual report questionnaire; MHLW, “Latest situation on synthetic drugs and responses to the 
threats in Japan Part II”, presented at the SMART Regional Workshop, Chiang Rai, Thailand, August 2018 and corresponding reports 
presented at 2016 and 2017 SMART Regional Workshops; National Center of Neurology and Psychiatry (NCNP), “2017 Nationwide 
General Population Survey on Drug Use in Japan”, March 2018. 
Figure 1. Estimated lifetime and past year drug use 
prevalence of high school students in Japan by drug 
type, 2018 
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Source: National Center of Neurology and Psychiatry (NCNP), 
“2018 Nationwide High School Survey on Drug Use in Japan”, 
2018 (accessed at https://www.ncnp.go.jp/nimh/yakubutsu/
report/pdf/highschool2018.pdf). 
Figure 2. Estimated lifetime drug use prevalence of 
male and female high school students in Japan by drug 
type, 2018 
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Source: NCNP, “2018 Nationwide High School Survey on Drug 
Use in Japan”, 2018 (accessed at https://www.ncnp.go.jp/
nimh/yakubutsu/report/pdf/highschool2018.pdf). 
Figure 3. Estimated past-year drug use prevalence of 
male and female high school students in Japan by drug 
type, 2018 
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Source: NCNP, “2018 Nationwide High School Survey on Drug 
Use in Japan”, 2018 (accessed at https://www.ncnp.go.jp/
nimh/yakubutsu/report/pdf/highschool2018.pdf). 
Figure 4. Perceived availability of drugs among Japanese 
high school students by drug type, 2018 
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Note: ‘Perceived availability’ means either easily obtainable or 
known ways to get drugs.  
Source: NCNP, “2018 Nationwide High School Survey on Drug 
Use in Japan”, 2018 (accessed at https://www.ncnp.go.jp/
nimh/yakubutsu/report/pdf/highschool2018.pdf). 
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Drug supply indicators  
Table 2. Seizures of selected drugs in Japan, 2014-2019*
Drug type Measurement 2014 2015 2016 2017 2018 2019*
Crystalline 
methamphetamine kg 570.2 431.8 1,521.4 1,136.6 1,206.7 2,316.5
“Ecstasy” tablets 608 1,074 5,122 3,244 12,307 74,057
Cannabis herb kg 166.6 104.6 159.7 270.5 337.3 344.7
Cannabis resin kg 36.7 3.9 1.0 21.9 3.1 ●
Cocaine kg 2.3 18.6 113.3 11.6 157.4 34.9
Heroin kg 0 2.0 0 70.3 0 0
Opium kg 0.2 0 0.7 0 0 0
Note: * Data are preliminary and only cover those reported from NPA; ● = Not reported
Source: UNODC, responses to the annual report questionnaire; NPA, “Latest situation on synthetic drugs and responses to the 
threats in Japan”, presented at the SMART Regional Workshop, Singapore, August 2019; NPA, “Drug Control in Japan”, presented 
at the 25th Asia-Pacific Operational Drug Enforcement Conference, Tokyo, Japan, February 2020. 
 
Figure 5. Number of drug-related arrests in Japan, 
2014-2018
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Source: MHLW, “Latest situation on synthetic drugs and 
responses to the threats in Japan”, presented at the SMART 
Regional Workshop, Singapore, August 2019. 
Figure 6. Embarkation points of methamphetamine 
trafficking to Japan by number of cases, 2018
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Source: Data from NPA presented by MHLW at the 2019 SMART 
Regional Workshop, Singapore, August 2019. 
Figure 7. Seizures of methamphetamine by mode of 
trafficking in Japan by weight, 2015-2019* 
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Note: * Data cover the first half of the year.
Source: Japan Customs, “Recent methamphetamine smuggling 
interdiction”, presented at Pre-operational meeting for 
Operation Ice Break, October, Seoul, the Republic of Korea; 
Official communication with Japan Customs, February 2020.    
Figure 8. Seizures of methamphetamine by mode of 
trafficking in Japan by number, 2015-2019* 
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Note: * Data cover the first half of the year.
Source: Japan Customs, “Recent methamphetamine smuggling 
interdiction”, presented at Pre-operational meeting for 
Operation Ice Break, October, Seoul, the Republic of Korea; 
Official communication with Japan Customs, February 2020.
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Table 3. Retail prices of selected drugs in Japan in US$, 2015-2018 
Drug type Unit 2015 2016 2017 2018
Crystalline 
methamphetamine 
Per gram 581 588 560 562
“Ecstasy” Per tablet 33.2 36.7 36 37.5
Cannabis herb  Per gram 41.5 55 55 47
Heroin Per gram 498.1 276 270 281.4
Cocaine Per gram ● ● ● 187.6
Note: ● = Not reported 
Source: UNODC, responses to the annual report questionnaire; NPA, “Latest situation on synthetic drugs and responses to the 
threats in Japan”, presented at the SMART Regional Workshop, Singapore, August 2019.
Figure 9. Number of arrests related to NPS in Japan, 
2014-2018
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Note: Data for each year in the figure 1 represent data collected 
during the period of April 1 – March 31 of that year based on 
the fiscal year of Japan.
Source: MHLW, “Latest situation on synthetic drugs and 
responses to the threats in Japan”, presented at the SMART 
Regional Workshop, Singapore, August 2019 and previous 
years. 
Figure 10. Number of NPS reported by Japan by 
substance group, 2014-2019* 
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Note: * Data as of 31 January 2020.  
Source: UNODC Early warning advisory on NPS. 
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Methamphetamine  
•	 Lao PDR is experiencing an increasing inflow of drugs trafficked from the Golden Triangle. The amount 
of crystalline methamphetamine seized annually has increased exponentially in recent years. The 
seizures of more than 5 tons of crystalline methamphetamine in 2019, the largest ever reported in the 
country, represents a more than a thirty-fold increase since 2015. (see Table 2). 
•	 Despite an increase in seizures in recent years, the average retail price of methamphetamine tablets 
has dropped to a record low of US$ 1 per tablet in 2019, indicating its wide availability on the market 
(see Figure 6).    
•	 The country remains a significant transit country for chemicals suspected to be used for illicit drug 
manufacture, with the amount of seizures reaching a record high in 2019 (see Table 2). Significantly 
in May 2019, authorities seized 10 tons of unspecified chemicals suspected to be methamphetamine 
precursors, which were destined for Myanmar.1 
“Ecstasy”2
•	 There is limited information on “ecstasy” use in Lao PDR. However, MDMA has been detected in some 
of the drug samples analysed by the authorities.3 
New Psychoactive Substances (NPS)
•	 There has been no reported use and trafficking of NPS in Lao PDR. 
Other drugs 
•	 Lao PDR remains a producer of opium, although its area under illicit opium poppy cultivation represents 
only a small proportion of the global total. Latest data show that the area under opium poppy cultivation 
has stabilised at low levels.4  
1  Lao National Commission for Drug Control and Supervision (LCDC), “Latest situation on synthetic drugs and responses to the threats in Lao 
PDR”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019.  
2  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of 
MDMA.   
3  LCDC, “Country briefing”, present at the Meeting of Drug Forensic Specialists, Beijing China, December 2019.
4  According to LCDC, in 2018, the estimated area under opium poppy cultivation in the country was 4,925 hectares, marking an 8% decrease 
compared to 2017. 
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Key facts and figures  
Drug demand indicators  
Table 1. Trend in use of selected drugs in Lao PDR, 2014-2019*
Drug type 2014 2015 2016 2017 2018 2019
Methamphetamine tablets      
Crystalline methamphetamine      
Cannabis herb      
Opium      
Heroin      
Note: * Based on expert perception provided by LCDC, Lao PDR. 
 = Increasing,  = Decreasing,   = Stable, ● = Not reported
Source: Drug Abuse Information Network for Asia and the Pacific (DAINAP). 
 
Figure 1. Number of drug users admitted for treatment, 
2014-2018
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Note: The data here only represent drug users admitted to 
the Somsanga Treatment and Rehabilitation Centre, and it 
should be interpreted with caution to understand the drug use 
situation in the country. 
Source: LCDC, “Latest situation on synthetic drugs and 
responses to the threats in Lao PDR”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019.  
Figure 2. Drug treatment centre admissions by drug 
type, 2018
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Note: The data here only represent drug users admitted to 
the Somsanga Treatment and Rehabilitation Centre, and it 
should be interpreted with caution to understand the drug use 
situation in the country.
Source: LCDC, “Latest situation on synthetic drugs and 
responses to the threats in Lao PDR”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019. 
Drug supply indicators  
Table 2. Seizures of selected drugs and chemicals in Lao PDR, 2014-2019 
Drug type Unit 2014 2015 2016 2017 2018 2019 
Methamphetamine 
tablets tablets 3,832,895 6,331,692 2,849,414 10,019,643 21,036,045 17,703,036
Crystalline 
methamphetamine kg 19.4 141.9 150.1 124.5 1,841.5 5,106
Cannabis herb kg 1,233.3 3,258 466 4,810.0 450.9 2,577
Cocaine kg 0 0 0 0 8.3 3
Heroin kg 181.7 134.8 221.0 149.5 281.3 174
Opium kg 12.8 51.6 137.7 142.9 103.8 89
Unspecified chemicals* kg 1,494.4 4,372.2 1,102.6 189.2 5,016.3 13,141
Note: * Include precursor chemicals; ● = Not reported 
Source: DAINAP; LCDC, “Latest situation on synthetic drugs and responses to the threats in Lao PDR”, presented at the 2019 SMART 
Regional Workshop, Singapore, August 2019; LCDC, “Law enforcement statistics for 2019”, February 2020. 
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Figure 3. Seizures of crystalline methamphetamine and 
methamphetamine tablets in Lao PDR, 2014-2019 
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Source: DAINAP; LCDC, “Latest situation on synthetic drugs and 
responses to the threats in Lao PDR”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019; LCDC, 
“Law enforcement statistics for 2019”, February 2020. 
Figure 4. Number of cases and arrests for drug-related 
offences in Lao PDR, 2014-2019 
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Source: DAINAP, LCDC, “Latest situation on synthetic drugs and 
responses to the threats in Lao PDR”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019; LCDC, 
“Law enforcement statistics for 2019”, February 2020.  
Figure 5. Seizures of unspecified chemicals suspected 
to be intended for illicit drug manufacture, 2014–2019
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Source: DAINAP; LCDC “Law enforcement statistics for 2019”, 
February 2020, and corresponding reports reported from 
previous years. 
Table 3. Average wholesale or retail prices of selected 
drugs in Lao PDR, 2019  
Drug type Unit Price (US$)
Methamphetamine tablets 
(retail)
tablet 1
Crystalline methamphetamine 
(wholesale)
kg 6,000
Heroin (wholesale) kg 14,500
Opium (wholesale) kg 600
Cannabis herb (wholesale) kg 70
Source: LCDC, “Latest situation on synthetic drugs and 
responses to the threats in Lao PDR”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019; Official 
communication with LCDC, February 2020. 
Figure 6. Average retail prices of methamphetamine 
tablets in Lao PDR in US$, 2013-2019*  
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Source: DAINAP; Official communication with LCDC, February 
2020. 
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Malaysia
Methamphetamine  
•	 The number of methamphetamine users brought into formal contact with authorities has been 
increasing in recent years, (see Figure 1), with the drug accounting for the largest proportion of 
treatment admissions in 2018 (see Table 2).
•	 There is a sharp increase in the amount of methamphetamine seized in recent years, with quantities of 
crystalline methamphetamine (almost 6 tons) and methamphetamine tablets (more than 1.6 million) 
seized in 2019 being the second largest on record (see Table 3).
•	 Despite increased seizures, wholesale prices of the drug have declined while purity remained stable in 
recent years (see Tables 5 and 6). 
•	 There has been a downward trend in the number of methamphetamine manufacturing facilities 
dismantled in the country (see Table 4), which could indicate that the drug is increasingly being sourced 
from overseas. 
“Ecstasy”1
•	 The available data for “ecstasy” show a mixed picture: while the number of “ecstasy” manufacturing 
facilities dismantled in 2019 decreased significantly in comparison to the preceding year (see Table 
4) and the use trend is perceived to have declined (Table 1), seizures remain comparatively high and 
number of users brought into formal contact with authorities has been increasing in recent years (see 
Tables 2 and 3). 
New Psychoactive Substances (NPS)
•	 The amount of ketamine seized annually has increased substantially in recent years and the country 
dismantled a clandestine ketamine laboratory in 2019 for the first time since 2016 (see Tables 3 and 
4).2 
•	 The amount of kratom leaves seized annually has increased significantly in recent years, with seizures 
of more than 180 tons in 2019 being the largest ever reported, constituting a six-fold increase since 
2015 (see Table 3).
•	 Between 2018 and July 2019, a total of 29 NPS were identified in the country, a majority of which were 
synthetic cathinones and synthetic cannabinoids (see Table 7).3 
Other drugs 
•	 While available data indicate that the local market for cocaine in Malaysia is small, national authorities 
seized a total of approximately 15 tons of cocaine in two separate seizures in 2019.4 
  
1  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of 
MDMA.   
2  National Anti-Drug Agency (NADA), Royal Malaysian Police (RMP), and the Department of Chemistry Malaysia (KIMIA), “Latest situation on 
synthetic drugs responses to the threats in Malaysia”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019.
3  Ibid. 
4  Royal Malaysian Police (RMP), “Country drug situation briefing”, presented at the Operation Ice Break Pre-Operational Meeting, Seoul, the 
Republic of Korea, October 2019. 
CAMBODIA
Summary of major trends and emerging concerns
MALAYSIA
62
Synthetic Drugs in East and Southeast Asia
Key facts and figures  
Drug demand indicators  
Table 1. Trend in use of selected drugs in Malaysia, 2015-2019*
Drug type 2015 2016 2017 2018 2019
Crystalline methamphetamine     
Methamphetamine pills     
“Ecstasy”     
Amphetamine     ●
Benzodiazepines     ●
Cannabis herb     
Heroin     
Ketamine     
Cocaine ● ● ● ● 
Kratom ●    
Note: * Based on expert perception provided by the NADA, Malaysia. 
 = Increase,  = Decrease,   = Stable, ● = Not reported
Source: UNODC, responses to the annual report questionnaire; DAINAP; Official communication with NADA, February 2020.  
Figure 1. Number of people who use drugs brought into formal contact with authorities in Malaysia by drug type, 
2016-2018
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Note: * Includes heroin and morphine. ** Mainly composed of ketamine and benzodiazepines.  
Source: DAINAP; NADA, RMP, and KIMIA, “Latest situation on synthetic drugs responses to the threats in Malaysia”, presented at 
the 2019 SMART Regional Workshop, Singapore, August 2019.
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Table 2. Drug treatment admissions by drug type and gender in Malaysia, 2018
Drug type
New admissions All admissions
Male Female Total Male Female Total 
Crystalline methamphetamine 8,118 457 8,575 10,998 533 11,531
Methamphetamine tablets 3,248 83 3,311 4,734 119 4,853
“Ecstasy” 57 16 73 79 17 96
Amphetamine 836 50 886 1,000 56 1,056
Opiates* 4,527 181 4,708 7,500 246 7,746
Cannabis 811 32 843 1,089 33 1,122
Benzodiazepines 14 9 23 16 10 26
Ketamine 3 0 3 30 0 3
Kratom 12 0 12 16 0 16
Total 17,626 828 18,434 25,462 1,014 26,449
Source: DAINAP; NADA, RMP and KIMIA, “Latest situation on synthetic drugs responses to the threats in Malaysia”, presented at 
the 2019 SMART Regional Workshop, Singapore, August 2019.
Drug supply indicators  
Table 3. Seizures of selected drugs in Malaysia, 2014-2019
Drug type Unit 2014 2015 2016 2017 2018 2019
Crystalline 
methamphetamine kg 1,212.7 1,138.5 718.5 1,553.3 6,851.8 5,831.4
Liquid 
methamphetamine lt/kg 41.8 lt 539.2kg 429 kg 460.0 lt 296.9 lt 249 lt 
Methamphetamine 
tabletsa tablets 557,337 538,176 895,499 847,334 2,512,444 1,672,778
“Ecstasy”b tablets 117,702 407,475 200,763 329,594 146,758
260.0 kg
“Ecstasy” powder kg 53.7 267.9 ● 430.6 337.4
Ketamine kg 240.3 48.4 380.0 506.4 217.1 1,261
Heroin kg 455.8 742.6 742.6 1,441.4 731.5 709.5
Benzodiazepines tablets / kg 467,133 tablets
4,038,733 
tablets
1,891,852 
tablets
2,756,552 
tablets 912.4 kg 85 kg
Cannabis herb kg 578.2 1,844.2 2,945.5 2,696.3 1,894.8 651.8
Cocaine kg 33.4 18.0 253.1 23 12.1 15,247.3
Codeine lt 1,548.5 3,169.1 5,616 10,216.3 37,263.9 13,312.6
Kratom leaf kg 15,541.4 28,961.4 124,717.9 81,028.6 87,564.8 180,181.1
Kratom liquid lt 45,429.9 206,175.8 274,421 89,060.1 233,525.9 101,516.7
Opium (raw and 
prepared) kg 0.1 0.1 0.7 0.1 0.2 0.4
Psychotropics Tablets/ kg 1,248,472 tablets
56,279 
tablets
39,979 
tablets
13,944 
tablets 0.8 kg 4.03 kg
Note: a Figures reported other than the number of tablets converted into estimated pill equivalents at 100 mg per tablet. b Figures 
reported other than the number of tablets converted into estimated tablet equivalents at 300 mg per tablet. 
Source: UNODC, responses to the annual report questionnaire; DAINAP; NADA, RMP and KIMIA, “Latest situation on synthetic 
drugs responses to the threats in Malaysia”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019. 
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Table 4. Number of illicit drug manufacturing facilities dismantled in Malaysia by drug type, 2015–2019  
Drug type 2015 2016 2017 2018 2019
Methamphetamine 16 14 9 10 7
Heroin 15 4 4 12 12
Ecstasy 7 5 4 11 1
Benzodiazepines 1 0 2 1 1
Ketamine 0 1 0 0 1
Other drugs 0 0 0 1 0
Source: UNODC, responses to the annual report questionnaire; DAINAP; NADA, RMP and KIMIA, “Latest situation on synthetic 
drugs responses to the threats in Malaysia”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019; KIMIA, 
“Country briefing”, presented at the Meeting of Drug Forensic Specialists, Beijing, China, December 2019. 
Table 5. Trends in wholesale / retail prices of selected drugs in Malaysia in US$, 2015–2019
Drug type Unit 2015 2016 2017 2018 2019
Methamphetamine
Tablet (retail)
per tablet 5.3 3–5 3.6 4.8 2.4-3.6
Crystalline methamphetamine
(wholesale)
per kg 28,080 16,000 – 
26,800
16,800 12,000 12,000
“Ecstasy” (retail) per tablet 11 8.4 – 10.8 12 7.2 7.2
Heroina (wholesale) per kg 4,704 3,744 – 
4,368
5,880 2,667 3,240
Ketamine (wholesale) per kg 4,800 6,000 – 
10,800
10,800 12,720 14,400
Cannabis (wholesale) per kg 632 486 – 681 586 576 480-600
Note: Prices reported in Malaysian Ringgit were converted with a conversion ratio of 1 MYR = 0.24 USD as of 1st March 2020;
 a Refers to heroin no.3. 
Source: DAINAP; NADA, RMP and KIMIA, “Latest situation on synthetic drugs responses to the threats in Malaysia”, presented at 
the 2019 SMART Regional Workshop, Singapore, August 2019.
Table 6. Typical purities (base form) of selected drugs in Malaysia, 2018-2019
Drug type 2018 2019
Crystalline methamphetamine 75 
(40 – 80)
75
(20 – 80)
“Ecstasy” 15 - 40 50
(10 – 60)
Heroin (No.3) 3
(1 – 5)
4
(3 – 70)
Ketamine 75
(70 – 85)
80
(50 – 85)
Source: NADA and Royal Malaysian Police, “Latest situation on synthetic drugs responses to the threats in Malaysia”, presented 
at the 2019 SMART Regional Workshop, Singapore, August 2019; KIMIA, “Country briefing”, presented at the Meeting of Drug 
Forensic Specialists, Beijing, China, December 2019; Official communication with NADA, February 2020.   
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Table 7. Types of NPS identified in Malaysia, 2018-2019* 
Number Substance Group Substance Name
1 Synthetic cathinones 4-methylmethcathinone (Mephedrone / 4MMC) 
2 Methylone (3,4-Methylenedioxymethcathinone / MDMC)
3 Ethylone (3,4- methylenedioxy-N-ethylcathinone / MDEC)
4 4-Methylethcathinone (4-MEC)
5 Methylenedioxy-N,N-dimethcathinone (Dimethylone )
6 3-fluoromethcathinone
7 4-chloromethcathinone
8 4-methylbuphedrone
9 4-Methyl-α-pyrrolidinobutiophenone (MPBP)
10 Synthetic cannabinoids JWH-018
11 AM-2201
12 JWH-250
13 XLR-11
14 MMB-FUBINACA (AMB – FUBINACA)
15 5F-INPB-22 (5-fluoro-NPB-22)
16 MDMB-CHMICA
17 5F-MDMB-PINACA (5-fluoro-ADB)
18 Piperazines 1-(3-Trifluoromethylphenyl)piperazine (3-trifluoromethylphenylpiperazine /
TFMPP) 
19 N-benzylpiperazine (Benzylpiperazine / BZP) 
20 1-(4-Fluorophenyl)piperazine
21 Phencyclidine-type substances Ketamine
22 Methoxetamine
23 Deschloro-N-ethyl-ketamine 
24 Tryptamines 5-methoxy-N,N-diisopropyltryptamine
25 5-Methoxy-N-isopropyl-N-methyltryptamine (5-methoxy-N,N-
methylisopropyltryptamine) 
26 Phenethylamines para-Methoxymethylamphetamine (para-methoxy-N-methylamphetamine / 
PMMA)
27 Other substances Etizolam
28 Plant-based substances Kratom
29 Khat
Note: * Data cover the first seven months of the year; Some of substances in the table have been under the international control 
but listed here for a monitoring purpose. 
Source: DAINAP; NADA, RMP and KIMIA, “Latest situation on synthetic drugs responses to the threats in Malaysia”, presented at 
the 2019 SMART Regional Workshop, Singapore, August 2019; Official communication with KIMIA, March 2020.
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Myanmar
Methamphetamine
•	 Methamphetamine manufacture in the north eastern part of Myanmar has expanded in recent years, 
with record seizures of the drug and some of its precursor chemicals in 2019 (see Tables 2 and 3).  
•	 Annual seizures of methamphetamine, in both crystalline and tablets forms, have increased significantly 
since 2017 (Table 2 and Figure 3).
•	 The types of chemicals seized in the country have diversified over the last two years and point to an 
increase in use of pre-precursors and/or non-scheduled precursor chemicals in the illicit manufacture 
of drugs in the Golden Triangle (see Table 3).1 
•	 The number of methamphetamine related treatment admissions decreased in 2019.2 However, expert 
perception indicates an increasing trend in its use over the last five years (see Table 1 and Figure 1). 
“Ecstasy”3
•	 In 2019, national authorities seized some quantities of safrole, a precursor for MDMA, in the Shan 
State. However, its use in the manufacture of “ecstasy” in the country has not been established.4 
New Psychoactive Substances (NPS)
•	 Seizures of ketamine in Myanmar remained high with more than 1 ton seized in 2019 (see Table 2). 
•	 Substantial quantities of kratom5 were seized in Myanmar in 2019 (see Table 2), which were largely 
intended for use in the southern part of the country.6   
Other drugs 
•	 Opium poppy cultivation in Myanmar continued to decline in 2019 and reached only 33,100 hectares 
(ha), marking a 42 percent decrease compared to 2014.7 
    
  
1  For more information, please see the regional chapter for methamphetamine in this report. 
2  Data from Government operated Drug Treatment Centres only.
3  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of 
MDMA.   
4  Central Committee for Drug Abuse Control (CCDAC), “2019 Precursor Situation in Myanmar”, at the Meeting of Drug and Precursor 
Intelligence Specialists, Mandalay, Myanmar, February 2020.
5  Kratom (Mitragyna speciosa) is a large tree found in tropical and sub-tropical regions of Southeast Asia. This plant-based substance contains 
many alkaloids, and when consumed can result in stimulant and sedative effects.
6  Chemical Examiner’s Office of the Myanmar Police Force, “Country briefing”, presented at the Meeting of Drug Forensic Specialists, Beijing, 
China, December 2019.
7  UNODC, “Myanmar Opium Survey 2019: Cultivation, Production and Implications”, February 2020. 
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Key facts and figures  
Drug demand indicators  
Table 1. Trend in use of selected drugs in Myanmar, 2014-2019
Drug type 2014 2015 2016 2017 2018 2019
Heroin      
Opium      
Methamphetamine tablets      
Crystalline 
methamphetamine ●   ●  ●
Cannabis   ●   
Note: * Based on expert perception provided by CCDAC, Myanmar.  
 = Increase, = Decrease,   = Stable, ● = Not reported
Source: UNODC, responses to the annual report questionnaire; DAINAP; Official communication with CCDAC, February 2019.   
Figure 1. Number of people admitted to drug treatment centres in Myanmar by drug type, 2014 – 2019
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Note: * Include opium and heroin. 
Source: DAINAP; CCDAC, “Synthetic drug situation in Myanmar”, presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019 and previous country reports presented at past SMART Regional Workshops; Official communication with CCDAC, 
March 2020. 
Drug supply indicators  
Table 2. Seizures of selected drugs in Myanmar, 2014-2019
Drug type Unit 2014 2015 2016 2017 2018 2019
Methamphetamine 
tablets tablets 12,650,000 49,950,000 98,353,463 74,001,667 106,702,365 108,719,071
Crystalline 
methamphetamine kg 47.1 2,261.7 2464.1 1,107.5 2,877.5 9,426.2
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Methamphetamine 
powdera kg 108.4 197.9 54.8 106.9 45.2 477.6
“Ecstasy” tablets 2,388,953 1 22 645,882 2,686 27,995
Heroinb kg 435.5 186.0 769.3 570.6 1,099.1 690.2
Opium (raw) kg 1,828.4 888.8 945.7 1,256.2 2,829.0 1,552.7
Cannabisc kg 205.5 87.7 188.8 99.4 142.4 364.8
Kratom kg 605.3 687.4 1409.4 652.1 1,833.9 2,542.6
Ketamined kg 4.2 3.1 940.2 75.1 2,360.2 1,096
Note: ● = Not reported. a Methamphetamine for processing into methamphetamine tablets. b  Reported as heroin No.4. c Combined 
herb and resin. d Figures reported in lt were converted into kg with the ratio 1 lt = 1 kg. 
Source: UNODC, responses to the annual report questionnaire; DAINAP; CCDAC, “Synthetic drug situation in Myanmar”, presented 
at the 2019 SMART Regional Workshop, Singapore, August 2019; CCDAC, “2019 Precursor Situation in Myanmar”, at the Meeting 
of Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, March 2020.
Figure 2. Drug related arrests and number of cases, 
2014–2019
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Source: DAINAP; CCDAC, “Synthetic drug situation in 
Myanmar”, presented at the 2019 SMART Regional Workshop 
Singapore, August 2019; Official communication with CCDAC, 
Mach 2020.       
Figure 3. Trends in the number of cases and seizures for 
methamphetamine, 2014-2019 
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Source: UNODC, responses to the annual report questionnaire; 
DAINAP; CCDAC, “Synthetic drug situation in Myanmar”, 
presented at the 2019 SMART Regional Workshop Singapore, 
August 2019; Official communication with CCDAC, Mach 2020. 
Table 3. Seizures of selected chemicals used in the illicit manufacture of drugs in Myanmar, 2014-2019
Drug type Unit 2014 2015 2016 2017 2018 2019
Ephedrine Kg 32.1 112.0 534.2 0 139.7 4.0
Pseudoephedrinea tablets 19,452,000 12,720,000 1,192,000 3,901,000 450,000 0
Phenylacetic acid lt 0 0 0 950 4,000 0
P-2-P lt ● 4,800 0 0 3,298 300
Acetic anhydride lt 1,297.5 260.0 16.0 1,318.3 40.0 4,140.1
Safrole lt 0 0 0 0 0 1,440
Thionyl chloride lt 0 0 0 0 16 11,600
Methyl Ethyl Ketone lt ● ● ● ● 7,860 9,600
Sodium cyanide lt ● ● ● 19,000 23,550 4,640
Benzyl cyanide lt ● ● ● ● ● 22,160
Tartaric acid lt ● ● ● ● 1,520 22,800
Caffeine Kg 431.5 9,532.3 19,847.5 5,885 20,759.5 19,226
Note: ●= Not reported; a The amount of pseudoephedrine found in tablets varies.
Source:  DAINAP; CCDAC, “Synthetic drug situation in Myanmar”, presented at the 2019 SMART Regional Workshop Singapore, 
August 2019; CCDAC, “2019 Precursor Situation in Myanmar”, at the Meeting of Drug and Precursor Intelligence Specialists, 
Mandalay, Myanmar, February 2020.
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Table 4. Typical purities of selected drugs in Myanmar (percentage), 2017-2019 
2017 2018 2019
Methamphetamine tablet 7.8 -23.6 9.1-18.8 5.2-17.2 
Crystalline methamphetamine 86.2-97.4 80-97.9 44.4-80.4
“Ecstasy” 46.2 43.3 42.8
Heroin 75.5 80.1 78.5
Note: Data in this table refer to the weight/weight (w/w) % expressed as the hydrochloride salt of methamphetamine. 
Source:  DAINAP; Chemical Examiner’s Office of the Myanmar Police Force, “Country briefing”, presented at the Meeting of Drug 
Forensic Specialists, Beijing, China, December 2019. 
Table 5. Typical wholesale and retail prices of selected drugs in Myanmar in US$, 2017 – 2019
Drug type Unit 2017 2018 2019
Methamphetamine tablet (retail) tablet 2.0 2.0 2.1
Crystalline methamphetamine (retail) g 20-24 14-18 ●
“Ecstasy” (retail) tablet 31 30 32.1
Cannabis herb (wholesale) kg 207 200 214
Note: ● = Not reported
Source:  DAINAP; CCDAC “Synthetic drug situation in Myanmar”, presented at the 2018 SMART Regional Workshop, Chiang Rai, 
Thailand, August 2018; Official communication with CCDAC, March 2020.     
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Methamphetamine  
• Crystalline methamphetamine remains the primary drug of concern in the Philippines, and accounts 
for a large majority of drug-related arrests and treatment admissions in 2019 (see Figures 1 and 3). 
• There are no reports of the dismantling of clandestine methamphetamine laboratories in the Philippines 
in 2019. However, the amount of crystalline methamphetamine seized in 2019 remains high and large-
scale shipments trafficked from countries in the Mekong region continue to be intercepted in the 
country.1 
• An analysis of methamphetamine samples seized in the Philippines between 2014 and 2019 showed 
that over 90 per cent of the samples were manufactured from either ephedrine or pseudoephedrine. 2
“Ecstasy”3
• Between 2018 and the first six months of 2019, less than 1 per cent of the total number of treatment 
admissions were due to the use of “ecstasy”.4 
New Psychoactive Substances (NPS)
•	 Some quantities of synthetic cannabinoids, including 5-Fluoro-MDMB-PINACA and 5-Fluoro-MDMB-
PICA, smuggled through parcel posts were seized between 2018 and the first half of 2019.5 
•	 Seizures of gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL), albeit limited, have been 
reported in the Philippines, where they are sold under the street name of ‘liquid ecstasy’.6  
Other drugs 
•	 Although the use of cocaine is limited in the Philippines, increasing amounts of cocaine were intercepted 
at sea and along the coastline of the Philippines in recent years (see Table 2).7 
   
1  For instance, national authorities seized 276 kg of crystalline methamphetamine in Manila in March 2019, and the drug was trafficked from 
the Golden Triangle via Viet Nam. Another case involving 147 kg of the drug originating from the Golden Triangle via Cambodia was reported 
in May 2019. In both cases, drugs were found in typical teabag packages used by organized crime groups operating in the Golden Triangle.  
2  Dangerous Drugs Board (DDB) and Philippines Drug Enforcement Agency (PDEA), “Country report”, presented at the Meeting of Drug 
Forensic Specialists, Beijing, China, December 2019.
3  Dangerous Drugs Board (DDB) and Philippines Drug Enforcement Agency (PDEA), “Country report”, presented at the Meeting of Drug 
Forensic Specialists, Beijing, China, December 2019.
4  DDB and PDEA, “Latest situation on synthetic drugs and responses to the threats in Philippines”, presented at the 2019 SMART Regional 
Workshop, Singapore, August 2019.   
5  Ibid.
6  Ibid. 
7  PDEA, “PDEA: ‘Floating Cocaine’ A Diversionary Tactic.”, Press Release # 064/19, February 2019 (accessed at https://pdea.gov.ph/2-
uncategorised/1328-pdea-floating-cocaine-a-diversionary-tactic).    
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Key facts and figures  
Drug demand indicators  
Table 1. Trend in use of selected drugs in the Philippines, 2014-2019 
Drug type 2014 2015 2016 2017 2018 2019
Crystalline methamphetamine     ● ●
Benzodiazepine     ● ●
Cannabis herb     ● ●
Inhalants     ● ●
Note: Based on expert perception provided by the Dangerous Drugs Board (DDB). Expert perception data is not available for 2018 
and 2019.
 = Increasing,  = Decreasing,   = Stable, ● = Not reported. 
Source: UNODC, responses to the annual report questionnaire; DAINAP; Official communication with DDB, October 2018. 
Figure 1. Proportions of methamphetamine-related 
treatment admissions among all treatment admissions, 
2014-2019*
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Note: * Data cover the first six months of the year.  
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; DDB and PDEA, “Latest situation on synthetic drugs 
and responses to the threats in Philippines”, presented at the 
2019 SMART Regional Workshop, Singapore, August 2019.  
Figure 2. Number of methamphetamine-related 
treatment admissions by gender, 2014–2019*
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Note: * Data cover the first six months of the year.  
Source: UNODC, responses to the annual report questionnaire; 
DAINAP; DDB and PDEA, “Latest situation on synthetic drugs 
and responses to the threats in Philippines”, presented at the 
SMART Regional Workshop, Singapore, August 2019. 
Drug supply indicators  
Table 2. Seizures of selected drugs and precursor chemicals in the Philippines, 2014 – 2019 
Drug type Unit 2014 2015 2016 2017 2018 2019*
Crystalline 
methamphetamine kg 718.5 350.8 2,210.5 1,053.9 785.8 1,996
Liquid 
methamphetamine lt 17.6 856.5 1,805.7 50.2 110.8 0
“Ecstasy” tablets 3,599 2,902 21,736 591 16,713 13,108
Benzodiazepine tablets 216 2,304 120 83 876 3
Cannabis herb kg 897.8 1,032.4 1,334.6 431.7 257.8 612.6
Heroin kg 0 2.0 0 0 0 0
Cocaine kg 69.9 11.5 70.6 9.9 94.6 344.8
Ketamine kg 0.1 ● 0.0a ● 0.0a 0.2
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GHB lt ● 3.1 ● 0 a ● 0a
GBL lt ● ● ● 0.9 0.7 2.3
Pseudoephedrine kg ● 2.1 ● 209.5 0 ●
Ephedrine kg 510.1 49.8 9.9 0.2 0.53 0.1
Note: ● = Not reported.
Source: UNODC, responses to the annual report questionnaire; DAINAP; DDB and PDEA, “Latest situation on synthetic drugs 
and responses to the threats in Philippines”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019; Official 
communication with PDEA, February 2020.   
Figure 3. Number of drug-related arrests in the 
Philippines by drug type, 2014–2019
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Source: UNODC, responses to the annual report questionnaire; 
DAINAP; DDB and PDEA, “Latest situation on synthetic drugs 
and responses to the threats in Philippines”, presented at the 
2019 SMART Regional Workshop, Singapore, August 2019; 
Official communication with PDEA, February 2020.    
Figure 4. Number of illicit methamphetamine facilities 
dismantled in the Philippines, 2010 – 2019
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Source: DAINAP; DDB and PDEA, “Latest situation on synthetic 
drugs and responses to the threats in Philippines”, presented 
at the 2019 SMART Regional Workshop, Singapore, August 
2019; Official communication with PDEA, February 2020.  
Table 3. Retail prices of selected drugs in the Philippines in US$, 2015-2019
Drug type Unit 2015 2016 2017 2018 2019
Crystalline 
methamphetamine per gram 29.6 – 317.6 25.8 – 236.6 163.7 130.1  136
“Ecstasy” per tablet 19 – 63.5 30 37.7 32.5 34
Cocaine per gram ● ● 99.3 101.4 106
Cannabis herb per gram ● ● 3.2 2.3 2.4
Source: UNODC, responses to the annual report questionnaire; DAINAP; DDB and PDEA, “Latest situation on synthetic drugs and 
responses to the threats in Philippines”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019; DDB and PDEA, 
“Country report”, presented at the Meeting of Drug Forensic Specialists, Beijing, China, December 2019; Official communication 
with PDEA, February 2020.    
Table 4. Purities of selected drugs analysed in the Philippines (percentage), 2015-2019*
2015 2016 2017 2018 2019
Crystalline 
methamphetamine 
67.3 82.4 87.7 72.5 78.2 
MDMA (“ecstasy”) - 47.5 31.4 45.5 40.1 
Note: * Data in this table refer to the weight/weight (w/w) % expressed as the hydrochloride salt of these substances.
Source: DDB and PDEA, “Latest situation on synthetic drugs and responses to the threats in Philippines”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019; DDB and PDEA, “Country report”, presented at the Meeting of Drug Forensic 
Specialists, Beijing, China, December 2019; Official communication with PDEA, February 2020.   
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Table 5. Types of NPS and emerging synthetic substances identified in the Philippines, 2018-2019*
Number Substance group Substance name 
1. Synthetic cathinones 4-methylethcathinone (4-MEC); 3,4-Methylenedioxy-N,N-
dimethcathinone; 4-chloro cathinone
2. Synthetic cannabinoids 5F-MDMB-PINACA; 5F-MDMB-PICA
3. Tryptamines Dimethyltryptamine (DMT)
4. Phenethylamines 4-bromo-2,5-dimethoxyphenethylamine (2C-B)
5 Others Gamma-Butyrolactone (GBL)
Note: * Data cover the first seven months of the year.  
Source: DDB and PDEA, “Latest situation on synthetic drugs and responses to the threats in Philippines”, presented at the 2019 
SMART Regional Workshop, Singapore, August 2019
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Methamphetamine 
•	 The number of users of psychotropic substances1 brought into formal contact with authorities, mostly 
in relation to crystalline methamphetamine, reached a record high in 2019 (see Figure 1).
•	 The quantities of methamphetamine seized annually remained high in 2019, with seizures of crystalline 
methamphetamine being the second largest on record and seizures of methamphetamine tablets 
reaching a record high (see Table 3). 
•	 An overwhelming majority of methamphetamine trafficked into the country in 2018 and 2019 originated 
from Southeast Asia (see Table 4), and nearly 80% of the total amount of methamphetamine seized in 
2019 were trafficked by air passengers (see Figure 4). 
•	 Small-scale methamphetamine manufacturing facilities continued to be dismantled in 2019 (see Figure 
2).
“Ecstasy”2
•	 The amount of “ecstasy” seized annually in the Republic of Korea has increased significantly since 2016 
(see Table 3). 
•	 The number of trafficking cases of the drug detected by national authorities has also been on the rise, 
with more than half reported to have originated from the Netherlands.3  
New Psychoactive Substances (NPS)
•	 National authorities continued to intercept several shipments of new psychoactive substances in 
recent years (see Table 3). 
Other drugs 
•	 The amount of cocaine seized annually reached a record high in 2019, primarily due to a trafficking 
case involving 100 kg of the drug believed to have originated from Colombia (see Table 3).4     
•	 The illicit market of cannabis remains a concern for the country, with annual quantities of cannabis 
seized in the last two years being the largest on record (see Table 3), and the number of cannabis users 
and suppliers brought into formal contact with authorities having increased significantly in recent years 
(see Table 2 and Figure 3).
  
1  Synthetic drugs, such as methamphetamine, ‘ecstasy’, LSD and NPS, are categorised as psychotropic substances according to the 
Government of Republic of Korea.   
2  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of 
MDMA.   
3  Supreme Prosecutors’ Office (SPO), “White paper on illicit drugs-related crime for 2018”, August 2019. 
4  Korean Coast Guard, “Combat against drugs in the sea”, presented at the Maritime Drug Trafficking in Southeast Asia, Bangkok, Thailand, 
October 2019. 
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Key facts and figures 
Drug demand indicators
Table 1. Trend in use of selected drugs in the Republic of Korea, 2014-2019*
Drug type 2014 2015 2016 2017 2018 2019
Crystalline methamphetamine      
Cannabis herb      
Other narcotics      
Note: * Based on expert perception provided by the Supreme Prosecutors’ Office (SPO)
 = Increase,  = Decrease,   = Stable, ● = Not reported
Source: UNODC, responses to the annual report questionnaire; Official communication with SPO, January 2020. 
Figure 1. Number of people who use drugs brought into formal contact with authorities in the Republic of Korea 
by drug type, 2014–2019
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Source: SPO, “White paper on illicit drugs-related crime for 2018”, and previous reports; SPO, “Monthly report on illicit-drug 
related crime for November 2019”, January 2020; Official communication with SPO, January 2020.
Table 2. Number of people admitted to drug treatment centres in the Republic of Korea, 2014-2018
Drug type 2014 2015 2016 2017 2018
Psychotropic substancesa 96 216 258 295 248
Cannabis 0 1 15 23 16
Narcoticsb 5 4 4 28 3
Total 101 221 277 346 267
Note: a Synthetic drugs, such as methamphetamine, ‘ecstasy’, LSD and NPS, are categorised as psychotropic substances according 
to the Government of Republic of Korea; b Drugs that have a natural constituent plant, such as opiates and cocaine are categorised 
as narcotics according to the Government of Republic of Korea.
Source: SPO, “White paper on illicit drugs-related crime”, Seoul, August 2015; Official communication with SPO, May 2016; Official 
communication with SPO, October 2018; Official communication with SPO, January 2020. 
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Drug supply indicators  
Table 3. Seizures of selected drugs in Korea, 2014-2019 
Drug type Unit 2014 2015 2016 2017 2018 2019
Crystalline methamphetamine kg 47.7 56.6 28.7 30.5 187.9 87.3
Methamphetamine tabletsa tablets 10,333 7,889 6,667 28,667 94,889 193,333
Ecstasyb tablets 720 637 3,690 1,633 9,393 10,464
Cannabis herb kg 23.3 22.0 75.5 40.1 89.1 81.9
Cannabis resin kg 0.3 0.3 0.1 1.3 0.1 2.7
Cannabis seed kg 4.4 2.9 1.9 1.2 1.2 0.4
Synthetic cannabinoids kg 0.1 0.4 0.2 0.2 0.5 1.7
Cocaine kg 0.0c 0.0c 10.9 0.1 88.3 106.9
Heroin g 1 5 0.0  3.7 2 0
Raw opium g 110 235 0 537 190 0
Khat kg 0 3,169 0 0 132.5 0
Note: a Figures reported other than the number of tablets converted into estimated tablet equivalents at 90 mg per tablet; b Figures 
reported other than the number of tablets converted into estimated tablet equivalents at 300 mg per tablet; c Less than 0.05 kg of 
the substance was seized.  
Source: UNODC, responses to the annual report questionnaire; SPO, “Synthetic drug situation in the Republic of Korea”, presented 
at the SMART Regional Workshop, Singapore, August 2019; Official communication with SPO, January 2020.
Figure 2. Number of methamphetamine manufacturing 
facilities dismantled, and amounts seized in the 
Republic of Korea, 2014-2019*
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Note: * Data cover the first eleven months of the year.
Source: SPO, “Country report”, presented at the Meeting of 
Drug Forensic Specialists, Beijing, China, December 2019. 
Figure 3. Number of people brought into formal contact 
with authorities for supplying drugs in the Republic of 
Korea (by drug type, 2014–2019)
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
2014 2015 2016 2017 2018 2019
Nu
m
be
r o
f p
eo
pl
e 
Psychotropic substances Cannabis Narco�cs
Source: SPO, “White paper on illicit drugs-related crime for 
2018”, and corresponding previous reports; SPO, “Monthly 
report on illicit-drug related crime for November 2019”, 
January 2020; SPO, “Synthetic drug situation in the Republic 
of Korea”, presented at the 2019 SMART Regional Workshop, 
Singapore, August 2019; Official communication with SPO, 
January 2020.
Table 4. Number of cases and amounts of 
methamphetamine seized in the Republic of Korea by 
embarkation point, 2018 and 2019 
Region Number of Cases Amounts Seized (kg)
Southeast Asia 121 260
North America 30 8
Europe 17 2
Africa 1 1
Note: Embarkation points do not necessarily mean source 
regions.  
Source: Korean Customs Service (KCS), “Combat against 
methamphetamine trafficking”, presented at the Operation Ice 
Break Pre-Operational Meeting, Seoul, the Republic of Korea, 
October 2019; Official communication with KCS, February 
2020. 
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Figure 4. Trends in modes of trafficking in methamphetamine by weight in the Republic of Korea, 2018-2019
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Source: KCS, “Combat against methamphetamine trafficking”, presented at the Operation Ice Break Pre-Operational Meeting, 
Seoul, the Republic of Korea, October 2019; Official communication with KCS, February 2020. 
Table 5. Purities* of crystalline methamphetamine samples analysed in the Republic of Korea, 2014-2019 
 Year 20<P≤80 80<P≤90 90<P≤98.5 P≥98.5
2014 1 4 37 1
2015 1 17 62 8
2016 3 0 55 8
2017 16 5 18 2
2018 0 1 47 16
2019** 4 9 39 11
Note: * Data in this table refer to the weight/weight (w/w) % expressed as the hydrochloride salt of methamphetamine. **Data for 
2019 cover the first eleven months of the year. 
Source: SPO, “Country report”, presented at the Meeting of Drug Forensic Specialists, Beijing, China, December 2019. 
Table 6. Retail prices of selected drugs in the Republic of Korea in US$, 2016-2019
Drug type Unit 2016 2017 2018 2019
Crystalline 
methamphetamine Per gram
422.5
(140.8 – 740.1) 363 388.8 450
“Ecstasy” Per tablet
70.4
(26.4 – 114.4)
89.1
(26.7 – 116)
77.1
(26.7 – 115.7) 11-180
Cannabis herb  Per gram 49.3(10.6 – 88.0)
89.1
(35.7 – 98.0)
80
(35.6 – 133.5) 27-200
Heroin Per gram 116 116 116 130
Cocaine Per gram ● ● ● 250-400
Ketamine Per gram ● ● ● 350
LSD Per sheet ● ● ● 21-42
Note: ● = Not reported.
Source: UNODC, responses to the annual report questionnaire; SPO, “Country report”, presented at the Meeting of Drug Forensic 
Specialists, Beijing, China, December 2019.
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Table 7. Types of synthetic cannabinoids smuggled to the Republic of Korea, 2016-2018
2016 2017 2018
1-Adamantyl-THPINACA 5F-APINACA (5F-AKB-48) MMB-FUBINACA (AMB-FUBINACA)
ADB-CHMINACA N-Adamantyl-1-fluoropentylindole-3-
carboxamide (STS-135)
5-fluoro-APINAC
AB-CHMINACA 5F-MDMB-PINACA (5F-ADB) 5F-AKB57 (5-fluoro APINAC)
5F-APINACA (5F-AKB-48) AB-CHMINACA 5F-MDMB-PICA
N-Adamantyl-1-fluoropentylindole-3-
carboxamide (STS-135)
5F-MMB-PICA (MMB-2201) ADBA-CHMINACA
5F-MDMB-PINACA (5F-ADB) 5F-AKB57 (5-fluoro APINAC)
5F-PB-22 5F-PB-22 
MDMB-CHMICA MMB-FUBINACA (AMB-FUBINACA)
XLR-11 (5F-UR-144)
JWH-073
Note:           The table lists only newly reported substances. 
Source: SPO, “White paper on illicit drugs-related crime for 2018”. 
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Singapore
Methamphetamine  
•	 In 2019, methamphetamine users continue to account for the largest proportion of drug treatment 
admissions (see Table 2) and drug users brought into formal contact with the authorities for the first 
time (see Figure 1). 
•	 The amount of crystalline methamphetamine seized annually has more than doubled since 2014 (see 
Table 4).  
“Ecstasy”1
•	 The amount of “ecstasy” seized annually in Singapore has increased steadily in recent years.  In 2019, 
the number of “ecstasy” users making their first formal contact with the authorities surpassed the 
number of heroin users for the first time.2   
•	 “Ecstasy” tablets found in Singapore are typically a mixture of MDMA and other psychoactive substances, 
including methamphetamine, amphetamine, ketamine, and various new psychoactive substances.3
New Psychoactive Substances (NPS)
•	 The NPS market in Singapore continues to evolve with synthetic cannabinoids making up a large 
majority of NPS identified in the samples analyzed (see Figures 2 and 3). 
•	 NPS users account for the second largest proportion of the total number of drug users brought into 
formal contact with the authorities for the first time in 2019, surpassing other traditional drug types 
such as cannabis, “ecstasy” and heroin. 
•	 Singapore has reported the emergence of illicitly manufactured Erimin 5 tablets4 containing several 
other benzodiazepines apart from nimetazepam, including phenazepam and etizolam.5
1 	“Ecstasy”	tablets	sold	in	the	country	may	contain	a	range	of	substances	in	varying	composition	and	quantities	in	addition	or	instead	of	MDMA.	
2 	Central	Narcotics	Bureau	(CNB),	“Drug	situation	report	2019”,	February	2020.
3 	Health	Sciences	Authority	(HSA)	of	Singapore,	“Drug	Analysis	in	Singapore.”,	presented	at	the	2019	SMART	Regional	Workshop,	Singapore,	
August 2019.
4 	Erimin	5	is	a	proprietary	product	of	Sumitomo	corporation,	and	its	licit	production	has	been	discontinued	since	2015.	The	proprietary	product	
contains	nimetazepam,	a	benzodiazepine,	which	 is	 controlled	 in	 Schedule	 IV	of	 the	Convention	on	Psychotropic	 Substances	of	1971.	 It	 is	
probable that current ‘Erimin 5’ seizures are manufactured illicitly and may or may not contain nimetazepam as well as a range of other 
substances.
5 	CNB	&	Health	Sciences	Authority	(HSA),	“Latest	situation	on	synthetic	drugs	and	responses	to	the	threats	in	Singapore”,	presented	at	the	2019	
SMART	Regional	Workshop,	Singapore,	August	2019.
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Key facts and figures  
Drug demand indicators  
Table 1. Trend in use of specific drugs in Singapore, 2014-2019* 
Drug type 2014 2015 2016 2017 2018 2019
Methamphetamine      
“Ecstasy”      
Cannabis	herb      
Heroin      
Ketamine      
Nimetazepam     ● ●
Cocaine      
Synthetic	cannabinoids ● ● ● ●  
Note: * Based on expert perception provided by CNB. 
 = Increase, = Decrease, 		=	Stable,	●	=	Not	reported
Source:	UNODC,	responses	to	the	annual	report	questionnaire;	DAINAP;	Official	communication	with	CNB,	February	2020.	
Table 2. Drug treatment admissions by drug type in Singapore, 2014-2019
Drug type 2014 2015 2016 2017 2018 2019
Methamphetamine 660 837 936 870 949 1,250
Amphetamine 1 0 0 0 ● ●
Ecstasy 7 0 1 8 8 19
Buprenorphine 0 0 0 0 ● ●
Cannabis	 73 85 97 71 77 69
Heroin 342 225 149 141 91 473
Ketamine 8 5 3 4 1 8
Benzodiazepines 16 18 7 2 ● ●
Other	drugs*	 32 43 70 56 131 261
Total* 1,139 1,213 1,263 1,152 1,257 2,080
Note: * Figures include other unspecified drugs; ● = Not reported; Data for 2019 are not directly comparable with data reported in 
previous years due to revisions to how repeat drug users will be managed under the rehabilitation-focused approach. As announced 
in Parliament on 15 Jan 2019, repeat drug users who do not face other concurrent drug or criminal charges and who admit to their 
drug abuse would be channeled towards the rehabilitation regime instead of being charged for their drug consumption offence. 
Source:	 UNODC,	 responses	 to	 the	 annual	 report	 questionnaire;	 DAINAP;	 CNB	 and	 HSA,	 “Latest	 situation	 on	 synthetic	 drugs	
and	responses	to	the	threats	in	Singapore”,	presented	at	the	2019	SMART	Regional	Workshop,	Singapore,	August	2019;	Official	
communication	with	CNB,	February	2020.	
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Figure 1. People who use drugs brought into formal contact with authorities for the first time in Singapore by drug 
type, 2019
Note: * Others include cocaine, ketamine, LSD and methadone.  
Source:	DAINAP;	CNB,	“Drug	situation	report	2019”,	February	2020,	and	previous	years;	CNB	and	HSA,	“Latest	situation	on	synthetic	
drugs	and	responses	to	the	threats	in	Singapore”,	presented	at	the	2019	SMART	Regional	Workshop,	Singapore,	August	2019.	
Table 3. Number of people who use drugs admitted to treatment centres by gender and drug type, 2019 
Drug type Male Female Total
Methamphetamine 961 289 1,250
Ecstasy 17 2 19
Cannabis 56 13 69
Heroin	 404 69 473
Ketamine 7 1 8
Unclassified	/	other	drugs	 216 45 261
Total 1,661 419 2,080
Source:	Official	communication	with	CNB,	February	2020.	
Drug supply indicators  
Table 4. Seizures of selected illicit drugs in Singapore, 2014-2019* 
Drug type Unit 2014 2015 2016 2017 2018 2019
Crystalline	
methamphetamine kg 12.5 15.6 18.3 22.2 19.3 31.1
Methamphetamine 
tablets tablets 248 142 242 827 5,236 775
“Ecstasy” tablets	/	g	 3,874	tablets
2,943 
tablets 
/2.49	g
3,891 
tablets	/	
97.9	g	
4,744	
tablets	/	
11.4 g
4,127	
tablets	/	
5.5 g
5,485 
tablets	/	
25.9
Cannabis	herb	 kg 35.0 44.3 54.0 44.1 61.8 27.8
Heroin a kg 67.5 53.7 52.4 36.9 58 37.8
Ketamine kg 2.5 2.3 1.5 1.0 1.1 3.4
Benzodiazepines	 tablets 17,682 33,686 19,550 19,580 7,873 8,454
Cocaine g 0.5 0 2 66.4 2,746.8 59.6
LSD stamp 4 130b 704 180 166 17
Synthetic	cathinones tablets	/	g
18	tablets	/	
0.1 g
2,444 
tablets	/		
490.9 g 
957	tablets	
/	3.3	g
219 tablets 
/	1.6	g
257	tablets	
/8.6	g
329 tablets 
/	1.4	g
Synthetic	cannabinoids tablets	/	g
452 tablets 
/	114.1	g
114 tablets 
/	145.9	g
13 tablets 
/13.5	g
1	tablet	/	
2506.8 g
72	tablets	/	
8162 g
0	tablets	/	
10,484.3 g
Note: * Data for 2019 are preliminary.   
a Refers to Heroin No. 3. b Some of these stamps contain NBOMe compounds and other NPS.  
Source:	UNODC,	responses	to	the	annual	report	questionnaire;	DAINAP;	CNB	and	HSA,	“Latest	situation	on	synthetic	drugs	and	
responses	to	the	threats	in	Singapore”,	presented	at	the	2019	SMART	Regional	Workshop,	Singapore,	August	2019;	CNB,	“Drug	
situation	report	2019”,	February	2020;	Official	communication	with	CNB,	February	2020.	
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Figure 2. Number of NPS identified from drug samples 
analysed by the Health Sciences Authority in Singapore 
by substance group 2016-2019*
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Note: * Data cover the first half of the year. 
Source:	CNB	and	HSA,	“Latest	situation	on	synthetic	drugs	and	
responses to the threats in Singapore”, presented at the 2019 
SMART	Regional	Workshop,	Singapore,	August	2019.
Figure 3. Top 10 NPS and other emerging synthetic 
substances identified in drug samples analyzed in 
Singapore, 2018 and 2019* 
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Methamphetamine 
•	 Methamphetamine remains the primary drug of concern in Thailand and continues to account for a 
large majority of treatment admissions in recent years (see Table 2). 
•	 Thailand recorded the largest seizures of methamphetamine by a single country in East and Southeast 
Asia during the period 2018-2019 with over 116 tons, as a result of the recent surge in the illicit 
manufacture of methamphetamine in the Golden Triangle.
•	 Despite the substantial seizures, retail prices for both tablet and crystalline methamphetamine have 
decreased by about two-thirds over the last decade (see Figures 4 and 5) suggesting a widespread 
availability of these drugs. 
•	 While the typical content of methamphetamine in tablet form has been decreasing since 2017, the 
typical purities of crystalline methamphetamine remain at very high levels (see Figures 2 and 3).
•	 In recent years, increasing quantities of sodium cyanide, a starting material for the controlled 
methamphetamine precursor P-2-P, have been seized in Thailand en route to the Golden Triangle (see 
Table 4). 
“Ecstasy”1
•	 The market for “ecstasy” remains insignificant in comparison to methamphetamine. However, 
quantities of the drug seized annually have been increasing since 2016 (see Table 3).
New Psychoactive Substances (NPS)
•	 The non-medical use of ketamine has been increasing in the country, as evidenced by increases in the 
number of treatment admissions and seizures of the drug (see Tables 2 and 3). The use of synthetic 
NPS2 remains limited in Thailand. 
Other drugs 
•	 The number of treatment admissions related to opiates has been stable over the last five years. The 
market for cocaine remains insignificant in the country. 
1  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of MDMA. 
2  Synthetic NPS excludes ketamine and plant-based substances. 
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Key facts and figures  
Drug demand indicators  
Table 1. Trend in use of selected drugs in Thailand, 2014-2019*
Drug type 2014 2015 2016 2017 2018 2019
Crystalline methamphetamine      
Methamphetamine tablets      
Ecstasy   ●   
Ketamine ● ● ●   
Cannabis herb      
Heroin      
Kratoma      
Cocaine  ● ● ●   
Note: * Expert perception based on the number of drug users brought into formal contact with authorities;  = Increasing,  = 
Decreasing,   = Stable, ● = Not reported.
Source: UNODC, responses to the annual report questionnaire; DAINAP; Official communication the Office of Narcotics Control 
Board (ONCB), February 2020.  
Table 2. Drug treatment admissions in Thailand by drug type, 2014-2019
Drug type 2014 2015 2016 2017 2018 2019
Methamphetamine 197,802 101,360 130,364 172,847 202,201 181,803
“Ecstasy” 224 202 8,422 524 560 409
Cannabis 13,360 8,720 15,206 14,616 12,976 15,514
Heroin 2,994 3,691 3,767 3,383 3,819 3,522
Opium 3,191 3,691 3,165 3,841 3,481 3,020
Ketamine 51 ● ● 381 704 1,069
Cocaine 32 30 84 25 22 12
Inhalants 7,033 1,787 1,693 1,456 1,288 1,038
Kratoma 5,687 1,727 5,327 6,828 5,384 4,429
Total 229,654 121,208 172,518 205,147 230,435 210,816
Note: a Includes users of kratom in leaf and liquid form. ● = Not reported.
Source: UNODC, responses to the annual report questionnaire; DAINAP; Official communication with ONCB, February 2020. 
Drug supply indicators  
Table 3. Seizures of selected drugs in Thailand, 2014-2019
Drug type Unit 2014 2015 2016 2017 2018 2019 
Methamphetamine 
tablets tablets 112,910,000 108,300,000 93,700,000 240,051,853 515,146,570 381,243,123
Crystalline 
methamphetamine kg 1,017 1,122.4 1,161 8,113.9 18,441.4 17,076.8
Ecstasya tablets 31,381 11,467 8,807 80,433 203,407 264,317 
Cannabis herb kg 32,199.4 24,554.3 3185.5 13,395.9 39,997 25,999.0 
Cocaine kg 28.6 45.7 50.1 54.7 49.7 41.4 
Heroin kg 480.0 202.5 147.5 599.4 1,085.4 667.2 
Ketamine kg 40.1 25.8 95.1 617.4 720.2 1,175.4 
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Kratom leaves kg 60,211.6 75,097.0 91,006.2 97,993.0 50,422.7 85,707.7 
Kratom liquid lt. 22,181.6 27,648.6 27,088.6 40,280.1 25,961.3 28,525.0
Note: a Figures reported in units other than number of tablets are converted into estimated tablet equivalent at 300 mg per tablet. 
Source: UNODC, responses to the annual report questionnaire; DAINAP; ONCB, “Synthetic drug situation in Thailand”, presented 
at the 2019 SMART Regional Workshop, Singapore, August 2019 and previous years; Official communication with ONCB, February 
2020. 
Table 4. Seizures of selected precursor chemicals and substances used as adulterants in illicit drugs in Thailand, 
2014-2019
Drug type Unit 2014 2015 2016 2017 2018 2019 
Pseudoephedrine 
(preparation) 
tablets 0 51,600 0 0 0 0
Pseudoephedrine 
(raw material) kg 6 0 0 0 0 0
Hydrochloric acid kg 0 0 0 0 0 15,950
Caffeine kg 0.1 0 0 0 0 0
Methylene chloride kg 0 20,000 0 0 0 0
Ammonium 
chloride kg 600 0 0 0 0 0
Sodium carbonate kg 1,800 0 0 0 0 0
Sodium cyanide kg 5,550 0 0 4,000 77,000 99,750
Ammonium 
hydroxide
lt. 0 0 0 0 90 0
Carbon kg 0 0 0 0 160 0
Source: ONCB, “Drugs and precursor chemical situation in Thailand”, presented at the Meeting of Drug and Precursor Intelligence 
Specialists, Mandalay, Myanmar, February 2020. 
Figure 1. Number of drug-related cases and arrests, 
2014-2019
0
50,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
2014 2015 2016 2017 2018 2019
Nu
m
be
r 
Arrests Cases
Source: DAINAP; ONCB, “Synthetic drug situation in Thailand”, 
presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019 and previous years; Official communication with 
ONCB, February 2020. 
Figure 2. Distribution of content of methamphetamine 
in tablet samples analysed in Thailand, 2014-2019 
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Note: * Data in this figure refer to the weight/weight (w/w) 
% expressed as the hydrochloride salt of methamphetamine; 
The average content of methamphetamine in tablet samples 
analysed in 2019 was 16.8 %. 
Source: ONCB, “Precursor chemical and drug profiling in 
Thailand”, presented at the Meeting of Drug Forensic Specialists, 
Beijing, China, December 2019; Official communication with 
ONCB, February 2020. 
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Figure 3. Distribution of purities of crystalline 
methamphetamine samples analysed in Thailand, 
2014-2019* 
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Note: * Data in this figure refer to the weight/weight (w/w) 
% expressed as the hydrochloride salt of methamphetamine. 
The average purity of crystalline methamphetamine samples 
analysed in 2019 was 94.9%. 
Source: ONCB, “Precursor chemical and drug profiling in 
Thailand”, presented at the Meeting of Drug Forensic Specialists, 
Beijing, China, December 2019; Official communication with 
ONCB, February 2020.  
Table 5. Typical wholesale and retail prices of selected 
illicit drugs in Thailand in US$, 2019
Drug type 
Methamphetamine tablet 
(per 2,000 tablets)
820 - 1,147
Methamphetamine tablet (per 
tablet) 
1.64 - 3.28
Crystalline methamphetamine 
(per kg)
8,197 - 13,115
Crystalline methamphetamine 
(per gram) 
33 - 49
“Ecstasy” (per tablet) 10 - 16
Heroin (per 700 gram) 9,836 - 13,115
Heroin (per g) 33 - 66
Cannabis herb (per kg) 164 - 262
Cannabis (per unit*) 1.64 - 3.28
Ketamine (per kg) 11,475 - 13,115
Ketamine powder (per gram) 16 - 33 
Note: * Approximately 5 g; Thailand reported prices with a 
conversion ratio of 30.5 THB = 1 US$
Source: Official communication with ONCB, February 2020.  
Figure 4. Retail prices of methamphetamine tablets per 
tablet, 2011, 2015 and 2019 
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Note: The high-low bars represent the upper and lower limits of 
the price range reported in addition to typical prices. When the 
typical price was not available, the mid-point was used. 
Source: UNODC, responses to the annual report questionnaire; 
Official communication with ONCB, February 2020. 
Figure 5. Retail prices of crystalline methamphetamine 
per gram, 2011, 2015 and 2019 
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Note: The high-low bars represent the upper and lower limits of 
the price range reported in addition to typical prices. When the 
typical price was not available, the mid-point was used. 
Source: UNODC, responses to the annual report questionnaire; 
Official communication with ONCB, February 2020.  
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Methamphetamine 
•	 Increasing trends in seizures and number of registered people who use drugs (see Figure 1 and Table 
2) indicate a rapid expansion of the methamphetamine market. 
•	 The record seizure of over 5.5 tons of crystalline methamphetamine in 2019, which exceeds the 
combined seizures reported in the preceding five years (see Table 2), illustrates the significant increase 
in the scale of methamphetamine trafficking targeting the country since late 2018.1
•	 The diversion and trafficking of precursor chemicals within and from Viet Nam is a growing concern. 
Chemicals discovered in a large-scale clandestine methamphetamine laboratory dismantled in 
September 2019 had been diverted from sources within the country.2 In addition, the two largest 
shipments of APAAN intercepted at points of entry in Europe in 2018 had originated in or transited 
Viet Nam. 3
“Ecstasy”4
•	 Clandestine “ecstasy” manufacturing facilities continued to be dismantled in 2019.5  
•	 The content of MDMA found in some of “ecstasy” tablets in Viet Nam is high, with over 50% of the 
total weight.6 
New Psychoactive Substances (NPS)
•	 Several NPS have been identified in Vietnam in recent years, a large proportion of which were synthetic 
cannabinoids (see Figures 5 and 6). 
•	 Record amounts of ketamine were seized in Viet Nam in 2019, driven by a single trafficking case 
involving more than 500 kg of the drug.7 
Other drugs 
•	 Several heroin trafficking cases indicate that Viet Nam continues to be used as a transit country for 
heroin trafficked into China. 8
1  According to the Standing Office on Drugs and Crime (SODC) of Viet Nam, there was no crystalline mthemaphetamine trafficking case 
involving more than 100 kg of the drug prior to late 2018; SODC, “Synthetic drug situation in Viet Nam”, presented at the 2019 SMART 
Regional Workshop, Singapore, August 2019.  
2  SODC, “Country briefing”, presented at the Meeting of Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, February 2020.  
3  International Narcotics Control Board (INCB), “Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and 
psychotrophic substances 2019”, February 2020. 
4  “Ecstasy” tablets sold in the country may contain a range of substances in varying composition and quantities in addition or instead of MDMA. 
5  SODC, “Country briefing”, presented at the Meeting of Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, February 2020.  
6  SODC, “Synthetic drug situation in Viet Nam”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019.
7  SODC, “Country briefing”, presented at the Meeting of Drug and Precursor Intelligence Specialists, Mandalay, Myanmar, February 2020.  
8  SODC, “Synthetic drug situation in Viet Nam”, presented at the 2019 SMART Regional Workshop, Singapore, August 2019.
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Drug demand indicators
Table 1. Trend in use of selected drugs in Viet Nam, 2014-2019*
Drug type 2014 2015 2016 2017 2018 2019
Crystalline methamphetamine   ●  ● ●
Methamphetamine tablets   ●  ● ●
Ecstasy  ● ●  ● ●
Cannabis herb   ●  ● ●
Heroin   ●  ● ●
Opium  ● ●  ● ●
Note: * Based on expert perception provided by SODC.  = Increase,  = Decrease,  = Stable, ●= Not reported 
Expert perception data is not available for 2018 and 2019.
Source: Drug Abuse Information Network for Asia and the Pacfiic (DAINAP). 
Figure 1. The number of registered drug users in Viet 
Nam, 2014–2019*
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Note: * Data cover the first eleven months of 2019; ATS are 
a group of substances comprised of synthetic stimulants, 
including amphetamine, methamphetamine, and ecstasy-
group substances.
Source: DAINAP; SODC, “Synthetic drug situation in Viet Nam”, 
presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019. 
Figure 2. Registered drug users in Viet Nam by age 
group, 2019*
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Note: * Data cover the first half of 2019. 
Source: SODC, “Synthetic drug situation in Viet Nam”, 
presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019. 
Drug supply indicators  
Figure 3. Number of drug-related cases and arrests in 
Viet Nam, 2014-2019
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Source: DAINAP; Official communication with SODC, February 
2020.  
Figure 4. Top 10 synthetic NPS and other emerging 
synthetic substances  identified in
Viet Nam by substance, 2018 
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Note: Excluding ketamine and plant-based substances. 
Source: SODC, “Synthetic drug situation in Viet Nam”, 
presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019, and previous country reports presented at past 
SMART Regional Workshops.
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Table 2. Seizures of selected drugs in Viet Nam, 2014-2019*
Drug type Unit 2014 2015 2016 2017 2018 2019* 
Methamphetamine 
tablets tablets 297,285 696,632 427,655 979,487 1,363,495 987,913
Crystallline 
methamphetamine kg 352 983 839.6 856.9 1,929 5,500.6
Cannabis herb kg 442 4,500 479.8
111 kg of 
‘fresh’ and 
376.4 kg of 
‘dried’
254.4 kg of 
“dried” 586
Cocaine kg 42.6 178 14.5 2.4 137 ●
Heroin kg 922 1,510 607.8 906.7 1,584.4 1,494
Ketamine kg ● ● 4 17.6 6.2 507.5
Opium kg 32 133.8 92.1 167.1 196.7 600
Khat Kg ● ● ● 5,600 2,500 ●
NPS (XLR-11, synthetic 
cannabinoids) kg ● ● 1.6 108 103.3 ●
Note: * Data For 2019 are preliminary and subject to change. 
Source: UNODC, responses to the annual report questionnaire; DAINAP; SODC, “Synthetic drug situation in Viet Nam”, presented 
at the 2019 SMART Regional Workshop, Singapore, August 2019, and previous country reports presented at past SMART Regional 
Workshops. 
Figure 5. Purities of selected drugs analysed in Viet 
Nam, 2017-2019*
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Note: * Data refer to the weight/weight (w/w) % expressed as 
the free base of these substances and is as of August 2019.The 
high-low bars represent the upper and lower limits of the purity 
ranges report in addition to the typical purity.
Source: SODC, “Synthetic drug situation in Viet Nam”, 
presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019, and previous country reports presented at past 
SMART Regional Workshops.
Figure 6. Top 10 synthetic NPS and other emerging 
synthetic substances identified in Viet Nam by 
substance, 2019*
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Note: * Data cover the first half of the year; Excluding ketamine 
and plant-based substances. 
Source: SODC, “Synthetic drug situation in Viet Nam”, 
presented at the 2019 SMART Regional Workshop, Singapore, 
August 2019, and previous country reports presented at past 
SMART Regional Workshops.
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